Dsrna molecule for regulating expression of APOC3
By designing specific sequences and modified double-stranded RNA (dsRNA) to inhibit APOC3 gene expression, the problems of in vivo stability and cellular uptake of siRNA were solved, achieving effective APOC3 gene inhibition and treatment of hypertriglyceridemia.
Patent Information
- Application Number
- PCT/CN2026/096980
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-02-11
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Existing siRNAs have poor stability in vivo and are difficult to be absorbed by tissues and cells, resulting in poor inhibition of APOC3 gene expression and difficulty in effectively treating diseases such as hypertriglyceridemia.
Double-stranded RNA (dsRNA) of specific length and sequence, including a sense strand and an antisense strand, was designed to suppress APOC3 gene expression by improving stability and cellular uptake efficiency through nucleotide modification.
It improves the stability and cellular uptake of dsRNA in vivo, effectively inhibits APOC3 gene expression, reduces plasma triglyceride levels, and decreases the risk of hypertriglyceridemia.
Smart Images

Figure PCTCN2026096980-FTAPPB-I100001 
Figure PCTCN2026096980-FTAPPB-I100002 
Figure PCTCN2026096980-FTAPPB-I100003
Abstract
Description
A dsRNA molecule that regulates APOC3 expression
[0001] This application claims priority to Chinese patent application 2025106231351, filed May 15, 2025; Chinese patent application 2025112647330, filed September 5, 2025; Chinese patent application 2025114845707, filed October 17, 2025; and Chinese patent application 2026102028517, filed February 11, 2026. The full text of the aforementioned Chinese patent applications is incorporated herein by reference. Technical Field
[0002] This invention relates to the field of RNA interference, and more specifically to compositions and methods that can be used for the expression of apolipoprotein C3. Background Technology
[0003] The apolipoprotein C (APOC) family includes four subtypes: APOC1, APOC2, APOC3, and APOC4. APOC3, first proposed in 1969, has 99 amino acid residues. Its mature form lacks the first 20 amino acid residues of the signal peptide. Mature APOC3 consists of 79 amino acids and is a relatively small apolipoprotein. APOC3 is the most abundant subtype in the APOC family, primarily expressed in hepatocytes and less frequently in intestinal epithelial cells. In the bloodstream, APOC3 binds to triglyceride-rich lipoproteins (TRLs) (composed of CM from the intestine and VLDL from the liver) and HDL. Additionally, a small amount of APOC3 binds to LDL. The distribution of APOC3 among these lipoproteins depends on individual metabolic status and varies between fasting, postprandial, and subjects with normal and hypertriglyceridemia plasma triglyceride levels.
[0004] Studies have found that APOC3 can increase plasma triglyceride levels by inhibiting lipoprotein lipase (LPL) activity, and further increase triglyceride and cholesterol levels by interfering with the clearance of TRLs and their residues by LDLR and LDL receptor-related protein 1 (LRP1). Decreased TRL clearance is closely associated with increased plasma APOC3 levels, suggesting that APOC3 could serve as a therapeutic target for reducing dyslipidemia and CVD risk.
[0005] There is a need in the field for APOC3 expression modulators to treat apolipoprotein C3-related disorders such as hypertriglyceridemia.
[0006] In recent years, inhibitors targeting APOC3 have emerged as novel therapeutic agents for these diseases. siRNA, as a new treatment approach, holds immense potential. Acting on intracellular mRNA, siRNA can directly silence target genes compared to traditional small-molecule drugs, thus fundamentally and more effectively preventing the occurrence and progression of diseases. However, due to its poor stability, siRNA is easily degraded by nucleases in vivo, is poorly absorbed by tissues and cells, and is prone to off-target effects, limiting its clinical application. Currently, there is an urgent need for an siRNA that can effectively inhibit intracellular APOC3 gene expression. Summary of the Invention
[0007] This invention provides double-stranded RNA (dsRNA), vectors, cells, and pharmaceutical compositions and kits comprising said dsRNA, vectors, or cells for inhibiting the expression of apolipoprotein C3 (APOC3) in cells, as well as methods for inhibiting or reducing apolipoprotein C3 (APOC3) gene expression or treating diseases or conditions that benefit from reduced apolipoprotein C3 (APOC3) expression using said dsRNA, vectors, cells, and pharmaceutical compositions and kits.
[0008] In a first aspect, the present invention provides a double-stranded nucleotide (dsRNA) for inhibiting the expression of apolipoprotein C3 (APOC3) in cells, said dsRNA comprising a sense strand and an antisense strand forming a double-stranded region, wherein the length of said sense strand and said antisense strand is each independently 15-30 nucleotides, and said antisense strand comprises at least 15 consecutive nucleotide sequences that differ from SEQ ID NO:1 by 1, 2, 3, 4 or 5 nucleotides.
[0009] SEQ ID NO: 1:UCACUGAGAAUACUGUCCCGU.
[0010] In some embodiments, the antisense strand has one or more nucleotide differences at positions 1, 2, 17, 18 and 19 selected from SEQ ID NO:1 in the 5'-3' direction.
[0011] In some embodiments, the antisense strand has one or two nucleotide differences in the first, second, 17, 18 and 19 of SEQ ID NO:1 in the 5'-3' direction.
[0012] In some implementations, the antisense chain includes, for example, N1N2ACUGAGAAUACUGUN. 17 N 18 N 19 GUN 22 N23 At least 15 consecutive nucleotide sequences as shown in (SEQ ID NO:2); wherein:
[0013] N 22 For non-existent, A or U;
[0014] N 23 For non-existent, A or U;
[0015] N1 is either U or A;
[0016] N2 can be C, U, or A;
[0017] N 17 For C or U;
[0018] N 18 It is C, G, or A; and,
[0019] N 19 It can be C, G, or U.
[0020] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For A and N 19 The answer is C.
[0021] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For C and N 19 For U.
[0022] In some implementations, N1 is U, N2 is C, and N 17 For U, N 18 For C and N 19 The answer is C.
[0023] In some implementations, N1 is U, N2 is C, and N 17 For C, N 18 For C and N 19 For U.
[0024] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For G and N 19 The answer is C.
[0025] In some implementations, N1 is U, N2 is U or A, N 17 For C, N 18 For C and N 19 It is G.
[0026] In some implementations, N1 is A, N2 is C, and N 17 For U, N18 For C and N 19 The answer is C.
[0027] In some implementations, N1 is U and N2 is A or U and N 17 For U, N 18 For C and N 19 The answer is C.
[0028] In some implementations, N1 is A, N2 is A, N 17 For U, N 18 For C and N 19 The answer is C.
[0029] In some implementations, N1 is U and N2 is A or U and N 17 For C, N 18 For A and N 19 The answer is C.
[0030] In some implementations, N1 is A, N2 is A or U, N 17 For C, N 18 For A and N 19 The answer is C.
[0031] In some implementations, N1 is U and N2 is A or U and N 17 For C, N 18 For C and N 19 For U.
[0032] In some implementations, N1 is A, N2 is A, N 17 For C, N 18 For C and N 19 For U.
[0033] In some implementation schemes, N 22 For A and N 23 For U.
[0034] In some implementation schemes, N 22 For U and N 23 The answer is A.
[0035] In some implementation schemes, N 22 For A and N 23 The answer is A.
[0036] In some implementation schemes, N 22 For U and N 23 For U.
[0037] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For A and N 19 For C, N 22For A and N 23 For U.
[0038] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For A and N 19 For C, N 22 For A and N 23 The answer is A.
[0039] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For A and N 19 For C, N 22 For U and N 23 The answer is A.
[0040] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For A and N 19 For C, N 22 For U and N 23 For U.
[0041] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For C, N 19 For U, N 22 For A and N 23 For U.
[0042] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For C, N 19 For U, N 22 For A and N 23 The answer is A.
[0043] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For C, N 19 For U, N 22 For U and N 23 The answer is A.
[0044] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For C, N 19 For U, N 22 For U and N 23 For U.
[0045] In some embodiments, the positive strand comprises at least 15 consecutive nucleotide sequences that differ from SEQ ID NO:3 by 1, 2, 3, 4 or 5 nucleotides.
[0046] SEQ ID NO:3: ACGGGACAGUAUUCUCAGUGA.
[0047] In some embodiments, the positive strand has one or more nucleotide differences at positions 3, 4, 5, 20 and 21 selected from SEQ ID NO:3 in the 5'-3' direction.
[0048] In some embodiments, the positive strand has one or two nucleotide differences in the 3rd, 4th, 5th, 20th and 21st nucleotides selected from SEQ ID NO:3 in the 5'-3' direction.
[0049] In some implementations, the justice chain includes, for example, ACN'3N'4N'5ACAGUAUUCUCAGUN'. 20 N' 21 At least 15 consecutive nucleotide sequences of the sequence shown in (SEQ ID NO:4); wherein:
[0050] N' 21 It can be U or A;
[0051] N' 20 For G, U, or A;
[0052] N'5 is either G or A;
[0053] N'4 is C, G, or U; and,
[0054] N'3 can be C, G, or A.
[0055] In some implementation schemes, N' 21 For U, N' 20 G is G, N'5 is G, N'4 is U and N'3 is G.
[0056] In some implementation schemes, N' 21 For U, N' 20 G is G, N'5 is G, N'4 is G and N'3 is A.
[0057] In some implementation schemes, N' 21 For A and N' 20 G is G, N'5 is A, N'4 is G and N'3 is G.
[0058] In some implementation schemes, N' 21 For A and N' 20 G is G, N'5 is G, N'4 is G and N'3 is A.
[0059] In some implementation schemes, N' 21 For U, N' 20 G is G, N'5 is G, N'4 is C and N'3 is G.
[0060] In some implementation schemes, N' 21 For A and N' 20 For U or A, N'5 is G, N'4 is G and N'3 is C.
[0061] In some implementation schemes, N' 21 For U, N' 20 G is G, N'5 is A, N'4 is G and N'3 is G.
[0062] In some implementation schemes, N' 21 For A and N' 20 For A or U, N'5 is A, N'4 is G and N'3 is G.
[0063] In some implementation schemes, N' 21 For U, N' 20 U is U, N'5 is A, N'4 is G and N'3 is G.
[0064] In some implementation schemes, N' 21 For A and N' 20 For A or U, N'5 is G, N'4 is U and N'3 is G.
[0065] In some implementation schemes, N' 21 For U, N' 20 For A or U, N'5 is G, N'4 is U and N'3 is G.
[0066] In some implementations, N'21 represents A and N' 20 For A or U, N'5 is G, N'4 is G and N'3 is A.
[0067] In some implementation schemes, N' 21 For U, N' 20 Let U be N'5, G be N'4, G be N'3, and A be N'3.
[0068] In some implementations, the dsRNA is siRNA.
[0069] In some embodiments, the length of the double-stranded region is 15-25 nucleotide pairs, preferably 16-23 nucleotide pairs, and more preferably 19-21 nucleotide pairs.
[0070] In some implementations, the antisense strand is 19, 20, 21, 22, or 23 nucleotides in length.
[0071] In some implementations, the length of the justice chain is 19, 20, or 21 nucleotides.
[0072] In some embodiments, the antisense strand is 21, 22, or 23 nucleotides long, and the sense strand is 19, 20, or 21 nucleotides long.
[0073] In some implementations, the antisense strand is 23 nucleotides long and the sense strand is 21 nucleotides long.
[0074] In some embodiments, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang of at least one nucleotide; for example, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having at least two nucleotides. In some specific embodiments, the overhang is selected from U, UU, UUU, AA, AG, GG, and UA. In other specific embodiments, the overhang is selected from U, UU, UUU, and AA.
[0075] In some embodiments, the antisense strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences, as shown in any of SEQ ID NO: 61, 67, 73, 75, 78, and 86-98.
[0076] In some preferred embodiments, the antisense chain comprises any of the sequences shown in SEQ ID NO: 61, 67, 73, 75, 78 and 86-98.
[0077] In some embodiments, the antisense strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences, as shown in SEQ ID NO:90 or SEQ ID NO:95.
[0078] In some embodiments, the antisense strand comprises a nucleotide sequence as shown in SEQ ID NO:90 or SEQ ID NO:95.
[0079] In some embodiments, the positive chain comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, or at least 21 consecutive nucleotide sequences, as shown in any of SEQ ID NO: 14, 20, 26, 28, 31, and 39-51.
[0080] In some preferred embodiments, the justice chain comprises any of the sequences shown in SEQ ID NO:14, 20, 26, 28, 31 and 39-51.
[0081] In some embodiments, the positive chain comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, or at least 21 consecutive nucleotide sequences, as shown in SEQ ID NO:43 or SEQ ID NO:48.
[0082] In some embodiments, the positive strand comprises a nucleotide sequence as shown in SEQ ID NO:43 or SEQ ID NO:48.
[0083] In some embodiments, the dsRNA comprises any of the following pairs of paired sense and antisense sequences:
[0084] (1): Justice chain: SEQ ID NO:14, Antisense chain: SEQ ID NO:61;
[0085] (2): Justice chain: SEQ ID NO:20, Antisense chain: SEQ ID NO:67;
[0086] (3): Justice chain: SEQ ID NO:26, Antisense chain: SEQ ID NO:73;
[0087] (4): Justice chain: SEQ ID NO:28, Antisense chain: SEQ ID NO:75;
[0088] (5): Justice chain: SEQ ID NO:31, Antisense chain: SEQ ID NO:78;
[0089] (6): Justice chain: SEQ ID NO:39, Antisense chain: SEQ ID NO:86;
[0090] (7): Justice chain: SEQ ID NO:40, Antisense chain: SEQ ID NO:87;
[0091] (8): Justice chain: SEQ ID NO:41, Antisense chain: SEQ ID NO:88;
[0092] (9): Justice chain: SEQ ID NO:42, Antisense chain: SEQ ID NO:89;
[0093] (10): Justice chain: SEQ ID NO:43, Antisense chain: SEQ ID NO:90;
[0094] (11): Justice chain: SEQ ID NO:44, Antisense chain: SEQ ID NO:91;
[0095] (12): Justice chain: SEQ ID NO:45, Antisense chain: SEQ ID NO:92;
[0096] (13): Justice chain: SEQ ID NO:46, Antisense chain: SEQ ID NO:93;
[0097] (14): Justice Chain: SEQ ID NO:47, Antisense Chain: SEQ ID NO:94;
[0098] (15): Justice chain: SEQ ID NO:48, Antisense chain: SEQ ID NO:95;
[0099] (16): Justice chain: SEQ ID NO:49, Antisense chain: SEQ ID NO:96;
[0100] (17): Justice chain: SEQ ID NO:50, Antisense chain: SEQ ID NO:97; and,
[0101] (18): Justice chain: SEQ ID NO:51, Antisense chain: SEQ ID NO:98.
[0102] In some embodiments, substantially all nucleotides of the sense strand and substantially all nucleotides of the antisense strand are modified nucleotides. In other embodiments, all nucleotides of the sense strand and all nucleotides of the antisense strand are modified nucleotides.
[0103] In some embodiments, the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of: 2'-O-methyl modification, 2'-fluoro modification, 2'-O-methoxyethyl (MOE) modification, 2'-deoxynucleotide, unlocked nucleic acid nucleotide (UNA), glycol nuclec acid nucleotide (GNA), (E)-vinylphosphonate nucleotide, reverse nucleotide, reverse abase-free nucleotide, and phosphate thioester nucleotides with inter-nucleotide bonds.
[0104] In some embodiments, the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of: 2'-O-methyl modification, 2'-fluoro modification, 2'-O-methoxyethyl (MOE) modification, 2'-deoxynucleotide, unlocked nucleic acid nucleotide (UNA), glycol nuclec acid nucleotide (GNA), reverse nucleotide, reverse abase-free nucleotide, and modifications involving inter-nucleotide thiophosphate bonds.
[0105] In some embodiments, the antisense strand has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1.
[0106] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 14, and 16.
[0107] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 6, 14, and 16.
[0108] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 6, 8, 9, 14, and 16.
[0109] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 2, 4, 6, 8, 10, 14, 16, 18.
[0110] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 2, 4, 6, 12, 14, 16, 18, 20.
[0111] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 14, and 16.
[0112] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 9, 14, and 16.
[0113] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 14, and 16.
[0114] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 12, 14, and 16.
[0115] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 14, 16, 20.
[0116] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 1, 2, 9, 14, 16.
[0117] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 1, 2, 10, 14, 16.
[0118] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 9, 10, 14, and 16.
[0119] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 9, 10, 14, and 16.
[0120] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 1, 2, 12, 14, 16.
[0121] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 12, 16.
[0122] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 2, 6, 7, 8, 9, 14, 16.
[0123] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 12, 14, and 16.
[0124] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 3, 10, 14, and 16.
[0125] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 4, 10, 14, and 16.
[0126] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 6, 10, 14, and 16.
[0127] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 8, 10, 14, and 16.
[0128] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 14, 16, and 18.
[0129] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 14, 16, 20.
[0130] In some implementations, the antisense strand has 1, 2, or 3 2'-deoxynucleotides (DNA).
[0131] In some embodiments, the antisense strand has one 2'-deoxynucleotide (DNA) and is located at position 12, 14, or 15 (counting from the 5' end). In some preferred embodiments, the antisense strand has one 2'-deoxynucleotide (DNA) and is located at position 15 (counting from the 5' end).
[0132] In some embodiments, the antisense strand has one, two, or three nucleotides modified with 2'-O-methoxyethyl (MOE).
[0133] In some embodiments, the antisense strand has one 2'-O-methoxyethyl (MOE) modified nucleotide and is located at position 9 or 10 (counting from the 5' end).
[0134] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 9 and 10 (counting from the 5' end).
[0135] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 3 and 15 (counting from the 5' end).
[0136] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 3 and 20 (counting from the 5' end).
[0137] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 3 and 21 (counting from the 5' end).
[0138] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 5 and 15 (counting from the 5' end).
[0139] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 5 and 20 (counting from the 5' end).
[0140] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 5 and 21 (counting from the 5' end).
[0141] In some embodiments, the antisense strand has 1-4 phosphate thioester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23.
[0142] In some embodiments, the antisense strand has phosphate ester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23.
[0143] In some embodiments, the antisense strand has a 2'-fluoro-modified nucleotide at position 1 (counting from the 5' end) and two 2'-O-methoxyethyl (MOE)-modified nucleotides at positions 5 and 15 (counting from the 5' end).
[0144] In some embodiments, the antisense strand has a 2'-fluorinated nucleotide at position 1 (counting from the 5' end) and a 2'-deoxynucleotide (DNA) at position 15 (counting from the 5' end).
[0145] In some embodiments, the antisense strand has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1, (counting from the 5' end) two 2'-O-methoxyethyl (MOE) nucleotides at positions 5 and 15, and (counting from the 5' end) one 2'-deoxynucleotide (DNA) at position 15.
[0146] In some embodiments, the antisense strand has five 2'-fluoromodified nucleotides (counting from the 5' end) at positions 1, 2, 10, 14, and 16, and two 2'-O-methoxyethyl (MOE) modified nucleotides (counting from the 5' end) at positions 5 and 15.
[0147] In some embodiments, the antisense strand has five 2'-fluoromodified nucleotides (counting from the 5' end) at positions 2, 10, 12, 14, and 16, and two 2'-O-methoxyethyl (MOE) modified nucleotides (counting from the 5' end) at positions 5 and 15.
[0148] In some embodiments, the antisense strand has five 2'-fluorinated nucleotides (counted from the 5' end) at positions 1, 2, 10, 14, and 16, and one 2'-deoxynucleotide (DNA) at position 15 (counted from the 5' end).
[0149] In some embodiments, the antisense strand has five 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 10, 14, and 16, two 2'-O-methoxyethyl (MOE) nucleotides (counting from the 5' end) at positions 5 and 15, and one 2'-deoxynucleotide (DNA) at position 15 (counting from the 5' end).
[0150] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0151] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0152] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0153] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0154] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 6, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0155] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0156] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0157] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 6, 8, 9, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 7, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0158] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0159] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0160] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 4, 6, 8, 10, 14, 16, and 18, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 5, 7, 9, 11, 12, 13, 15, 17, 19, 20, 21, 22, and 23; and / or
[0161] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0162] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0163] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 4, 6, 12, 14, 16, 18, and 20, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 5, 7, 8, 9, 10, 11, 13, 15, 17, 19, 21, 22, and 23; and / or
[0164] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0165] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0166] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 14, and 16, and nucleotides with 2'-O-methyl modification at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0167] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0168] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0169] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 9, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0170] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0171] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0172] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0173] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0174] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0175] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 12, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0176] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0177] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0178] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 14, 16, and 20, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or
[0179] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0180] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0181] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 9, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0182] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0183] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0184] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0185] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0186] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0187] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 9, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0188] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0189] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0190] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 9, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0191] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0192] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0193] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 12, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0194] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0195] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0196] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 12, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at position 9; and nucleotides with 2'-O-methyl modification at positions 3, 4, 5, 6, 7, 8, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0197] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0198] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0199] (i) (counting from the 5' end) 2'-fluoro modified nucleotides at positions 1, 2, 12, 14, and 16; 2'-O-methoxyethyl modified nucleotide at position 10; and 2'-O-methyl modified nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0200] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0201] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0202] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 12, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 9 and 10; and nucleotides with 2'-O-methyl modification at positions 3, 4, 5, 6, 7, 8, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0203] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0204] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0205] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 3 and 15; and nucleotides with 2'-O-methyl modification at positions 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0206] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0207] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0208] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 3, 4, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0209] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0210] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0211] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0212] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0213] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0214] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 14, and 16; 2'-deoxynucleotides (DNA) at position 12; and 2'-O-methylated nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0215] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0216] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0217] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 12, and 16; 2'-deoxynucleotides (DNA) at position 14; and 2'-O-methyl nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0218] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0219] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0220] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 12, 14, and 16; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methylated nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0221] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0222] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0223] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 10, 14, and 16; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methylated nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0224] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0225] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0226] (i) (counting from the 5' end) 2'-fluoro-modified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl-modified nucleotides at positions 3 and 20; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl-modified nucleotides at positions 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or
[0227] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0228] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0229] (i) (counting from the 5' end) 2'-fluoro-modified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl-modified nucleotides at positions 3 and 21; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl-modified nucleotides at positions 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 22, and 23; and / or
[0230] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0231] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0232] (i) (counting from the 5' end) 2'-fluoromodified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl modified nucleotides at positions 5 and 20; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl modified nucleotides at positions 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or
[0233] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0234] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0235] (i) (counting from the 5' end) 2'-fluoromodified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl modified nucleotides at positions 5 and 21; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl modified nucleotides at positions 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 22, and 23; and / or
[0236] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0237] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0238] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 10, 12, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0239] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0240] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0241] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 12, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0242] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0243] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0244] (i) (counting from the 5' end) nucleotides with 2'-fluoro modification at positions 2, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0245] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0246] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0247] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 3, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 4, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0248] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0249] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0250] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 3, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0251] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0252] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0253] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 4, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0254] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0255] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0256] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 4, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0257] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0258] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0259] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 5, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0260] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0261] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0262] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 6, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0263] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0264] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0265] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 6, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0266] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0267] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0268] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 8, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0269] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0270] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0271] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 8, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0272] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0273] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0274] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 10, 14, 16, and 18; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 17, 19, 20, 21, 22, and 23; and / or
[0275] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0276] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0277] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 14, 16, and 18, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 19, 20, 21, 22, and 23; and / or
[0278] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0279] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0280] (i) (counting from the 5' end) nucleotides with 2'-fluoro modification at positions 2, 10, 14, 16, and 20; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 21, 22, and 23; and / or
[0281] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0282] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0283] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 14, 16, and 20, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or
[0284] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0285] In some implementations, the positive chain has a length of 19, 20, or 21 nucleotides.
[0286] In some embodiments, the positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 13 and 15.
[0287] In some embodiments, the positive strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 9, 10, 11, and 13.
[0288] In some embodiments, the positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11 and 15.
[0289] In some embodiments, the positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13, and 15.
[0290] In some embodiments, the positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 11, 13 and 15.
[0291] In some implementations, the positive strand has 1, 2, or 3 2'-deoxynucleotides (DNA).
[0292] In some implementations, the positive strand has 1, 2 or 3 2'-deoxynucleotides (DNA), one of which is located at position 20 (counting from the 5' end).
[0293] In some implementations, the positive strand has 1, 2, or 3 2'-deoxynucleotides (DNA), and one of them is located at position 1, 2, 3, or 4 (counting from the 5' end).
[0294] In some implementations, the positive strand has one 2'-deoxynucleotide (DNA), and one of them is located at position 3 or 4 (counting from the 5' end).
[0295] In some implementations, the positive strand has one 2'-deoxynucleotide (DNA), and one of them is located at position 3 (counting from the 5' end).
[0296] In some implementations, the positive strand has one 2'-deoxynucleotide (DNA), and one of them is located at position 4 (counting from the 5' end).
[0297] In some embodiments, the positive strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 13 and 15, and one 2'-deoxynucleotide (DNA) at position 3 or 4 (counting from the 5' end).
[0298] In some implementations, the positive strand has one 2'-deoxynucleotide (DNA) and is located at position 7, 10, or 20 (counting from the 5' end).
[0299] In some implementations, the positive strand has two 2'-deoxynucleotides (DNA), one of which is located at position 1, 2, 3 or 4 (counting from the 5' end), and the other is located at position 20 (counting from the 5' end).
[0300] In some implementations, the positive strand has 1, 2, or 3 unlocked nucleic acid nucleotides (UNA).
[0301] In some embodiments, the positive strand has 1-4 phosphate thioester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21.
[0302] In some embodiments, the positive strand has phosphate ester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0303] In some embodiments, the positive strand has a length of 21 nucleotides and has
[0304] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 9, 10, 11, and 13, and nucleotides with 2'-O-methyl modifications at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20, and 21; and / or
[0305] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0306] In some embodiments, the positive strand has a length of 21 nucleotides and has
[0307] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 9, 10, 11, and 15, and nucleotides with 2'-O-methyl modifications at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 13, 14, 16, 17, 18, 19, 20, and 21; and / or
[0308] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0309] In some embodiments, the positive strand has a length of 21 nucleotides and has
[0310] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 9, 10, 11, 13, and 15, and nucleotides with 2'-O-methyl modifications at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 16, 17, 18, 19, 20, and 21; and / or
[0311] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0312] In some embodiments, the positive strand has a length of 21 nucleotides and has
[0313] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13, and 15; 2'-deoxynucleotides (DNA) at position 4; and 2'-O-methyl nucleotides at positions 1, 2, 3, 5, 6, 7, 8, 12, 14, 16, 17, 18, 19, 20, and 21; and / or
[0314] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0315] In some embodiments, the positive strand has a length of 21 nucleotides and has
[0316] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13, and 15; 2'-deoxynucleotides (DNA) at position 3; and 2'-O-methyl nucleotides at positions 1, 2, 4, 5, 6, 7, 8, 12, 14, 16, 17, 18, 19, 20, and 21; and / or
[0317] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0318] In some embodiments, the antisense strand has a length of 23 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1 and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) 2'-fluorinated nucleotides at positions 13 and 15.
[0319] In some embodiments, the antisense strand has a length of 23 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1 and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at positions 13 and 15 and a 2'-deoxynucleotide (DNA) at position 3.
[0320] In some embodiments, the antisense strand has a length of 23 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at positions 13 and 15, and a 2'-deoxynucleotide (DNA) at position 4.
[0321] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end) and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end).
[0322] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end), and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end), and 2'-deoxynucleotide (DNA) at position 3.
[0323] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end), and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end), and 2'-deoxynucleotide (DNA) at position 4.
[0324] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 12, 14, and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 13 and 15, and 2'-deoxynucleotide (DNA) at position 4.
[0325] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 12, 14, and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 13 and 15, and 2'-deoxynucleotide (DNA) at position 3.
[0326] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 12, 14 and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 13 and 15.
[0327] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 10, 14 and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 9, 10, 11, 13 and 15.
[0328] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 1, 2, 10, 14 and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 9, 10, 11, 13 and 15, and 2'-deoxynucleotide (DNA) at position 3.
[0329] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 1, 2, 10, 14 and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 9, 10, 11, 13 and 15, and 2'-deoxynucleotide (DNA) at position 4.
[0330] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 12, 14, and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 9, 10, 11, 13, and 15, and 2'-deoxynucleotide (DNA) at position 4.
[0331] In some embodiments, the antisense strand has a length of 23 nucleotides and has (counting from the 5' end) 2'-fluorinated nucleotides at positions 2, 10, 12, 14, and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13, and 15, and 2'-deoxynucleotide (DNA) at position 3.
[0332] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 12, 14, and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 9, 10, 11, 13, and 15.
[0333] In some embodiments, the first nucleotide at the 5' end of the antisense strand is selected from the following structures:
[0334] Where Base is a base A, U, G, C, T or other nucleotide bases, and R is H, methoxy, F or methoxyethoxy.
[0335] In some embodiments, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0336] In some implementations, the antisense chain comprises an antisense chain sequence selected from any of the items shown in Table 4.
[0337] In some embodiments, the antisense strand comprises an antisense strand sequence selected from any one of SEQ ID NO:665, 776-806, 851, and 963-993.
[0338] In some implementations, the justice chain comprises a sequence of justice chains selected from any of the items shown in Table 2.
[0339] In some embodiments, the justice chain comprises a justice chain sequence selected from any one of SEQ ID NO:203 and 314-344.
[0340] In some embodiments, the dsRNA comprises a pair of sense and antisense sequences selected from any of the pairs in Tables 5-1, 5-2, and 5-3.
[0341] In some embodiments, the dsRNA comprises a pair of sense and antisense sequences selected from any of the pairs in Table 5-1.
[0342] In some embodiments, the dsRNA is further conjugated to a ligand moiety comprising N-acetylgalactosamine, preferably with the 3' end of the positive strand conjugated to the ligand moiety.
[0343] In some embodiments, the ligand has the following structure:
[0344] This indicates the position where the dsRNA is attached to the positive strand via a phosphate group or a thiophosphate group.
[0345] In some embodiments, the ligand is selected from the group consisting of formulas II to XXXI:
[0346] Where Y is either O or S and n is an integer between 3 and 6 (Equation XXIV)
[0347] Where Y is either O or S and n is an integer from 3 to 6 (equation XXV)
[0348] Where X is O or S (Equation XXVII)
[0349] This indicates the position where the dsRNA is attached to the positive strand via a phosphate group or a thiophosphate group.
[0350] In some embodiments, the ligand is selected from the following structures:
[0351] This indicates the linking bond between the ligand and dsRNA or siRNA.
[0352] In some embodiments, the dsRNA is coupled to the ligand as shown below.
[0353] Where X is O or S, and in some implementations, X is O.
[0354] In some implementations, the justice chain comprises a sequence of justice chains selected from any of the items shown in Table 3.
[0355] In some embodiments, the justice chain comprises a justice chain sequence selected from any one of SEQ ID NO:389 and 500-530.
[0356] In some embodiments, the dsRNA comprises a pair of sense and antisense sequences selected from any of the pairs in Table 5-2.
[0357] In a second aspect, the present invention provides a modified double-stranded nucleotide (dsRNA) comprising a sense strand and an antisense strand forming a double-stranded region, wherein the nucleotide sequence of the sense strand is such as 5'-X1X2X3X4X5X6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X19 X 20 X 21 As shown in -3', where X1-X 21 Each base is independently A, U, G, C, T, or other nucleotide bases; and:
[0358] (1)X 13 and / or X 15 Nucleotides that are 2'-fluorinated; and / or,
[0359] (2) X3, X4 and X 20 One or more of them are 2'-deoxynucleotides (DNA).
[0360] In some implementations, the dsRNA is siRNA.
[0361] In some embodiments, substantially all nucleotides of the sense strand and substantially all nucleotides of the antisense strand are modified nucleotides. In other embodiments, all nucleotides of the sense strand and all nucleotides of the antisense strand are modified nucleotides.
[0362] In some implementation schemes, X 13 and X 15 It is a nucleotide with a 2'-fluorinated modification, and X3, X4 or X 20 It is a 2'-deoxynucleotide (DNA).
[0363] In some implementation schemes, X 13 and X 15 X3 or X4 is a 2'-fluorinated nucleotide, and X3 or X4 is a 2'-deoxynucleotide (DNA). In some embodiments, X9, X... 10 and X 11 One or more of the nucleotides are 2'-fluorinated.
[0364] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 It is a nucleotide modified with 2'-fluorine.
[0365] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated nucleotide, and X2 is a 2'-deoxynucleotide (DNA).
[0366] In some implementation schemes, X9, X 10 X 11 X 13and X 15 X1 is a 2'-fluorinated nucleotide, and X4 is a 2'-deoxynucleotide (DNA).
[0367] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 It is a nucleotide with 2'-fluorination modification, and X 20 It is a 2'-deoxynucleotide (DNA).
[0368] In some implementations, the nucleotides at other positions are nucleotides modified with 2'-O-methyl.
[0369] In some implementations, X1 and X2 are linked by 3',5'-thiophosphate diester bonds and / or X2 and X3 are linked by 3',5'-thiophosphate diester bonds.
[0370] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 It is a 2'-fluorinated nucleotide, and X1-X8, X 12 X 14 and X 16 -X 21 It is a nucleotide modified with 2'-O-methyl.
[0371] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 It is a nucleotide modified with 2'-O-methyl.
[0372] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X2 is a 2'-deoxynucleotide (DNA), and X3 is a 2'-deoxynucleotide (DNA). X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 It is a nucleotide modified with 2'-O-methyl, and X1 and X2 are linked by 3',5'-phosphothioester bonds and X2 and X3 are linked by 3',5'-phosphothioester bonds.
[0373] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 It is a nucleotide modified with 2'-O-methyl.
[0374] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1-X3, X5-X8, X4 are 2'-fluorinated nucleotides, X4 is 2'-deoxynucleotide (DNA), X1-X3, X5-X8, X4 are 2'-fluorinated nucleotides, X5-X8 are 2'-fluorinated nucleotides, X4 is 2'-deoxynucleotide (DNA), X5-X8 are 2'-fluorinated nucleotides, ... 12 X 14 and X 16 -X 21 It is a nucleotide modified with 2'-O-methyl, and X1 and X2 are linked by 3',5'-phosphothioester bonds and X2 and X3 are linked by 3',5'-phosphothioester bonds.
[0375] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X is a nucleotide with a 2'-fluorine modification. 20 It is a 2'-deoxynucleotide (DNA) and X1-X8, X 12 X 14 and X 16 -X 19 and X 21 It is a nucleotide modified with 2'-O-methyl.
[0376] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X is a nucleotide with a 2'-fluorine modification. 20 It is a 2'-deoxynucleotide (DNA), X1-X8, X 12 X 14 and X 16 -X 19 and X 21 It is a nucleotide modified with 2'-O-methyl, and X1 and X2 are linked by 3',5'-phosphothioester bonds and X2 and X3 are linked by 3',5'-phosphothioester bonds.
[0377] In some embodiments, the nucleotide sequence of the antisense strand is such as 5'-Y1Y2Y3Y4Y5Y6Y7Y8Y9Y 10 Y 11 Y 12 Y 13 Y 14 Y 15 Y 16 Y 17 Y 18 Y 19 Y 20 Y 21 Y 22 Y 23 As shown in -3', where Y1-Y 21 Each of the bases is independently A, U, G, C, T, or other nucleotide bases; Y 22 and / or Y 23 It exists or does not exist; if it exists, Y 22 and Y 23 Each of the bases is independently A, U, G, C, T or other nucleotide bases.
[0378] In some implementation schemes, Y1, Y2, Y3, Y4, Y6, Y8, Y 10 Y 12 Y 14 Y 15 Y 16 Y 18 and Y 20 One or more of the nucleotides are 2'-fluorinated, such as 3, 4 or 5.
[0379] In some implementation schemes, Y1, Y2, Y 10 Y 14 and Y 16 It is a nucleotide modified with 2'-fluorine.
[0380] In some implementation schemes, Y2, Y 10 Y 12 Y 14 and Y 16 It is a nucleotide modified with 2'-fluorine.
[0381] In some implementation schemes, Y2, Y 14 and Y 16 It is a nucleotide modified with 2'-fluorine.
[0382] In some implementation schemes, Y2, Y3, Y 10 Y 14 and Y 16 It is a nucleotide modified with 2'-fluorine.
[0383] In some implementation schemes, Y2, Y4, Y 10 Y 14 and Y 16 It is a nucleotide modified with 2'-fluorine.
[0384] In some implementation schemes, Y2, Y6, Y 10 Y 14 and Y 16 It is a nucleotide modified with 2'-fluorine.
[0385] In some implementation schemes, Y2, Y8, Y 10 Y 14 and Y 16 It is a nucleotide modified with 2'-fluorine.
[0386] In some implementation schemes, Y2, Y 10 Y 14 Y 16 and Y 18 It is a nucleotide modified with 2'-fluorine.
[0387] In some implementation schemes, Y2, Y 10 Y 14 Y 16 and Y 20 It is a nucleotide modified with 2'-fluorine.
[0388] In some implementation schemes, Y2, Y5, Y 10 Y 14 and Y 16 It is a nucleotide modified with 2'-fluorine.
[0389] In some implementation schemes, Y2, Y 10 Y 14 Y 15 and Y 16 It is a nucleotide modified with 2'-fluorine.
[0390] In some implementations, Y5 and / or Y 15 It is a nucleotide modified with 2'-O-methoxyethyl.
[0391] In some implementations, Y5 and Y 15 It is a nucleotide modified with 2'-O-methoxyethyl.
[0392] In some implementation schemes, Y 15 It is a 2'-deoxynucleotide (DNA).
[0393] In some implementations, the nucleotides at other positions are nucleotides modified with 2'-O-methyl.
[0394] In some embodiments, the first nucleotide at the 5' end of the antisense strand is selected from the following structures:
[0395] Where Base is a base A, U, G, C, T or other nucleotide bases, and R is H, methoxy, F or methoxyethoxy.
[0396] In some embodiments, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0397] In some implementations, the relationships between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 One or more of them are linked by 3',5'-thiophosphate diester bonds.
[0398] In some implementation schemes, Y1, Y2, Y 10 Y 14 and Y 16 These are nucleotides with 2'-fluorination modification, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds.
[0399] In some implementation schemes, Y1, Y2, Y 10 Y 14 and Y 16 These are nucleotides with 2'-fluorination modification, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide.
[0400] In some implementation schemes, Y1, Y2, Y 10 Y 14 and Y16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds.
[0401] In some implementation schemes, Y1, Y2, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide.
[0402] In some implementation schemes, Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl and between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds.
[0403] In some implementation schemes, Y2, Y 10 Y 12 Y 14 and Y 16Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide.
[0404] In some implementation schemes, Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl and between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds.
[0405] In some implementation schemes, Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide.
[0406] In some implementation schemes, Y2, Y 14 and Y 16Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0407] In some implementation schemes, Y2, Y5, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0408] In some implementation schemes, Y2, Y 10 Y 14 Y 15 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0409] In some implementation schemes, Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y4-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0410] In some implementation schemes, Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y4, Y6-Y9, Y 11 -Y13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0411] In some implementation schemes, Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y3, Y5-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0412] In some implementation schemes, Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0413] In some implementation schemes, Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y5, Y7-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0414] In some implementation schemes, Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y7-Y9, Y 11 -Y 13 and Y 17 -Y 23It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0415] In some implementation schemes, Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y3-Y7, Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0416] In some implementation schemes, Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y7, Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0417] In some implementation schemes, Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0418] In some implementation schemes, Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 Y 19-Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0419] In some implementation schemes, Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 Y 17 -Y 19 and Y 21 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0420] In some implementation schemes, Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 17 -Y 19 and Y 21 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0421] In some implementation schemes, Y1, Y2, Y 10 Y 14 and Y 16 Y is a nucleotide with a 2'-fluorine modification. 15 It is a 2'-deoxynucleotide (DNA), Y3-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-phosphothioester bonds; optionally, the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotides.
[0422] In some implementation schemes, X9, X10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X2 is a 2'-deoxynucleotide (DNA), and X3 is a 2'-deoxynucleotide (DNA). X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 These are nucleotides modified with a 2'-O-methyl group, and X1 and X2 are linked by 3',5'-phosphothioester bonds; Y1, Y2, Y... 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds.
[0423] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide.
[0424] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide.
[0425] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y...21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds.
[0426] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 These are nucleotides with 2'-fluorination modification, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds.
[0427] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 These are nucleotides with 2'-fluorination modification, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide.
[0428] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 It is a 2'-fluorinated nucleotide, and X1-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds.
[0429] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 These are nucleotides with 2'-fluorination modification, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds.
[0430] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0431] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0432] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X21 Nucleotides modified with 2'-O-methyl; Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0433] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y7-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0434] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y7, Y9, Y11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0435] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0436] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 17 -Y 19 and Y 21 -Y 23It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0437] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y4-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0438] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y3, Y5-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0439] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y5, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0440] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y5, Y7-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0441] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y3-Y7, Y9, Y 11 -Y 13 Y15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0442] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0443] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 Y 17 -Y 19 and Y 21 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0444] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide.
[0445] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide.
[0446] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide.
[0447] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 15 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0448] In some implementation schemes, X9, X 10 X 11X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0449] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0450] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y4, Y 10 Y 14and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0451] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y7-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0452] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y7, Y9, Y 11 -Y 13 and Y 17 -Y 23It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0453] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0454] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 17 -Y 19 and Y 21 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0455] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y4-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0456] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y3, Y5-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0457] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21Nucleotides modified with 2'-O-methyl; Y2, Y5, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0458] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y5, Y7-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0459] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y3-Y7, Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0460] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0461] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 Y 17 -Y 19 and Y 21 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0462] In some implementation schemes, X9, X 10 X 11 X13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 15 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0463] In some implementation schemes, X9, X 10 X 11 X 13 and X 15 X is a nucleotide with a 2'-fluorine modification. 20 It is a 2'-deoxynucleotide (DNA), X1-X8, X 12 X 14 and X 16 -X 19 and X 21 These are nucleotides modified with a 2'-O-methyl group, and X1 and X2 are linked by 3',5'-phosphothioester bonds; Y1, Y2, Y... 10 Y 14 and Y 16 Y is a nucleotide with a 2'-fluorine modification. 15 It is a 2'-deoxynucleotide (DNA), Y3-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-phosphothioester bonds; optionally, the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotides.
[0464] In some embodiments, the dsRNA is further conjugated to a ligand moiety comprising N-acetylgalactosamine, preferably with the 3' end of the positive strand conjugated to the ligand moiety.
[0465] In some embodiments, the ligand has the following structure:
[0466] This indicates the position where the dsRNA is attached to the positive strand via a phosphate group or a thiophosphate group.
[0467] In some embodiments, the ligand is selected from the group consisting of formulas II to XXXI:
[0468] Where Y is either O or S and n is an integer between 3 and 6 (Equation XXIV)
[0469] Where Y is either O or S and n is an integer from 3 to 6 (equation XXV)
[0470] Where X is O or S (Equation XXVII)
[0471] This indicates the position where the dsRNA is attached to the positive strand via a phosphate group or a thiophosphate group.
[0472] In some embodiments, the ligand is selected from the following structures:
[0473] This indicates the linking bond between the ligand and dsRNA or siRNA.
[0474] In some embodiments, the dsRNA is coupled to the ligand as shown below.
[0475] Where X is O or S, and in some implementations, X is O.
[0476] In some implementations, the dsRNA is used to suppress the expression of apolipoprotein C3 (APOC3) in cells.
[0477] In some embodiments, the antisense strand comprises at least 15 consecutive nucleotide sequences that differ from SEQ ID NO:1 by 1, 2, 3, 4 or 5 nucleotides.
[0478] In some embodiments, the antisense strand has one or more nucleotide differences at positions 1, 2, 17, 18 and 19 selected from SEQ ID NO:1 in the 5'-3' direction.
[0479] In some embodiments, the antisense strand has one or two nucleotide differences in the first, second, 17, 18 and 19 of SEQ ID NO:1 in the 5'-3' direction.
[0480] In some implementations, the antisense chain includes, for example, N1N2ACUGAGAAUACUGUN. 17 N 18 N 19 GUN 22 N 23 At least 15 consecutive nucleotide sequences as shown in (SEQ ID NO:2); wherein:
[0481] N 22 For non-existent, A or U;
[0482] N 23 For non-existent, A or U;
[0483] N1 is either U or A;
[0484] N2 can be C, U, or A;
[0485] N 17 For C or U;
[0486] N 18 It is C, G, or A; and,
[0487] N 19 It can be C, G, or U.
[0488] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For A and N 19 The answer is C.
[0489] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For C and N 19 For U.
[0490] In some implementations, N1 is U, N2 is C, and N 17 For U, N 18 For C and N 19 The answer is C.
[0491] In some implementations, N1 is U, N2 is C, and N 17 For C, N 18 For C and N19 For U.
[0492] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For G and N 19 The answer is C.
[0493] In some implementations, N1 is U, N2 is U or A, N 17 For C, N 18 For C and N 19 It is G.
[0494] In some implementations, N1 is A, N2 is C, and N 17 For U, N 18 For C and N 19 The answer is C.
[0495] In some implementations, N1 is U and N2 is A or U and N 17 For U, N 18 For C and N 19 The answer is C.
[0496] In some implementations, N1 is A, N2 is A, N 17 For U, N 18 For C and N 19 The answer is C.
[0497] In some implementations, N1 is U and N2 is A or U and N 17 For C, N 18 For A and N 19 The answer is C.
[0498] In some implementations, N1 is A, N2 is A or U, N 17 For C, N 18 For A and N 19 The answer is C.
[0499] In some implementations, N1 is U and N2 is A or U and N 17 For C, N 18 For C and N 19 For U.
[0500] In some implementations, N1 is A, N2 is A, N 17 For C, N 18 For C and N 19 For U.
[0501] In some implementation schemes, N 22 For A and N 23 For U.
[0502] In some implementation schemes, N22 For U and N 23 The answer is A.
[0503] In some implementation schemes, N 22 For A and N 23 The answer is A.
[0504] In some implementation schemes, N 22 For U and N 23 For U.
[0505] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For A and N 19 For C, N 22 For A and N 23 For U.
[0506] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For A and N 19 For C, N 22 For A and N 23 The answer is A.
[0507] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For A and N 19 For C, N 22 For U and N 23 The answer is A.
[0508] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For A and N 19 For C, N 22 For U and N 23 For U.
[0509] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For C, N 19 For U, N 22 For A and N 23 For U.
[0510] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For C, N 19 For U, N 22 For A and N 23 The answer is A.
[0511] In some implementations, N1 is A, N2 is C, and N17 For C, N 18 For C, N 19 For U, N 22 For U and N 23 The answer is A.
[0512] In some implementations, N1 is A, N2 is C, and N 17 For C, N 18 For C, N 19 For U, N 22 For U and N 23 For U.
[0513] In some embodiments, the positive strand comprises at least 15 consecutive nucleotide sequences that differ from SEQ ID NO:3 by 1, 2, 3, 4 or 5 nucleotides.
[0514] In some embodiments, the positive strand has one or more nucleotide differences at positions 3, 4, 5, 20 and 21 selected from SEQ ID NO:3 in the 5'-3' direction.
[0515] In some embodiments, the positive strand has one or two nucleotide differences in the 3rd, 4th, 5th, 20th and 21st nucleotides selected from SEQ ID NO:3 in the 5'-3' direction.
[0516] In some implementations, the justice chain includes, for example, ACN'3N'4N'5ACAGUAUUCUCAGUN'. 20 N' 21 At least 15 consecutive nucleotide sequences of the sequence shown in (SEQ ID NO:4); wherein:
[0517] N' 21 It can be U or A;
[0518] N' 20 For G, U, or A;
[0519] N'5 is either G or A;
[0520] N'4 is C, G, or U; and,
[0521] N'3 can be C, G, or A.
[0522] In some implementation schemes, N' 21 For U, N' 20 G is G, N'5 is G, N'4 is U and N'3 is G.
[0523] In some implementation schemes, N' 21 For U, N' 20 G is G, N'5 is G, N'4 is G and N'3 is A.
[0524] In some implementation schemes, N' 21 For A and N' 20 G is G, N'5 is A, N'4 is G and N'3 is G.
[0525] In some implementation schemes, N' 21 For A and N' 20 G is G, N'5 is G, N'4 is G and N'3 is A.
[0526] In some implementation schemes, N' 21 For U, N' 20 G is G, N'5 is G, N'4 is C and N'3 is G.
[0527] In some implementation schemes, N' 21 For A and N' 20 For U or A, N'5 is G, N'4 is G and N'3 is C.
[0528] In some implementation schemes, N' 21 For U, N' 20 G is G, N'5 is A, N'4 is G and N'3 is G.
[0529] In some implementation schemes, N' 21 For A and N' 20 For A or U, N'5 is A, N'4 is G and N'3 is G.
[0530] In some implementation schemes, N' 21 For U, N' 20 U is U, N'5 is A, N'4 is G and N'3 is G.
[0531] In some implementation schemes, N' 21 For A and N' 20 For A or U, N'5 is G, N'4 is U and N'3 is G.
[0532] In some implementation schemes, N' 21 For U, N' 20 For A or U, N'5 is G, N'4 is U and N'3 is G.
[0533] In some implementations, N'21 represents A and N' 20 For A or U, N'5 is G, N'4 is G and N'3 is A.
[0534] In some implementation schemes, N' 21 For U, N' 20 Let U be N'5, G be N'4, G be N'3, and A be N'3.
[0535] In some embodiments, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang of at least one nucleotide; for example, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having at least two nucleotides. In some specific embodiments, the overhang is selected from U, UU, UUU, AA, AG, GG, and UA. In other specific embodiments, the overhang is selected from U, UU, UUU, and AA.
[0536] In some embodiments, the antisense strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences, as shown in any of SEQ ID NO: 61, 67, 73, 75, 78, and 86-98.
[0537] In some preferred embodiments, the antisense chain comprises any of the sequences shown in SEQ ID NO: 61, 67, 73, 75, 78 and 86-98.
[0538] In some embodiments, the antisense strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences, as shown in SEQ ID NO:90 or SEQ ID NO:95.
[0539] In some embodiments, the antisense strand comprises a nucleotide sequence as shown in SEQ ID NO:90 or SEQ ID NO:95.
[0540] In some embodiments, the positive chain comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, or at least 21 consecutive nucleotide sequences, as shown in any of SEQ ID NO: 14, 20, 26, 28, 31, and 39-51.
[0541] In some preferred embodiments, the justice chain comprises any of the sequences shown in SEQ ID NO:14, 20, 26, 28, 31 and 39-51.
[0542] In some embodiments, the positive chain comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, or at least 21 consecutive nucleotide sequences, as shown in SEQ ID NO:43 or SEQ ID NO:48.
[0543] In some embodiments, the positive strand comprises a nucleotide sequence as shown in SEQ ID NO:43 or SEQ ID NO:48.
[0544] In some embodiments, the dsRNA comprises any of the following pairs of paired sense and antisense sequences:
[0545] (1): Justice chain: SEQ ID NO:14, Antisense chain: SEQ ID NO:61;
[0546] (2): Justice chain: SEQ ID NO:20, Antisense chain: SEQ ID NO:67;
[0547] (3): Justice chain: SEQ ID NO:26, Antisense chain: SEQ ID NO:73;
[0548] (4): Justice chain: SEQ ID NO:28, Antisense chain: SEQ ID NO:75;
[0549] (5): Justice chain: SEQ ID NO:31, Antisense chain: SEQ ID NO:78;
[0550] (6): Justice chain: SEQ ID NO:39, Antisense chain: SEQ ID NO:86;
[0551] (7): Justice chain: SEQ ID NO:40, Antisense chain: SEQ ID NO:87;
[0552] (8): Justice chain: SEQ ID NO:41, Antisense chain: SEQ ID NO:88;
[0553] (9): Justice chain: SEQ ID NO:42, Antisense chain: SEQ ID NO:89;
[0554] (10): Justice chain: SEQ ID NO:43, Antisense chain: SEQ ID NO:90;
[0555] (11): Justice chain: SEQ ID NO:44, Antisense chain: SEQ ID NO:91;
[0556] (12): Justice chain: SEQ ID NO:45, Antisense chain: SEQ ID NO:92;
[0557] (13): Justice chain: SEQ ID NO:46, Antisense chain: SEQ ID NO:93;
[0558] (14): Justice Chain: SEQ ID NO:47, Antisense Chain: SEQ ID NO:94;
[0559] (15): Justice chain: SEQ ID NO:48, Antisense chain: SEQ ID NO:95;
[0560] (16): Justice chain: SEQ ID NO:49, Antisense chain: SEQ ID NO:96;
[0561] (17): Justice chain: SEQ ID NO:50, Antisense chain: SEQ ID NO:97; and,
[0562] (18): Justice chain: SEQ ID NO:51, Antisense chain: SEQ ID NO:98.
[0563] In some implementations, the antisense chain comprises an antisense chain sequence selected from any of the items shown in Table 4.
[0564] In some embodiments, the antisense strand comprises an antisense strand sequence selected from any one of SEQ ID NO:665, 776-806, 851, and 963-993.
[0565] In some implementations, the justice chain comprises a sequence of justice chains selected from any of the items shown in Table 2.
[0566] In some embodiments, the justice chain comprises a justice chain sequence selected from any one of SEQ ID NO:203 and 314-344.
[0567] In some implementations, the justice chain comprises a sequence of justice chains selected from any of the items shown in Table 3.
[0568] In some embodiments, the justice chain comprises a justice chain sequence selected from any one of SEQ ID NO:389 and 500-530.
[0569] In some embodiments, the dsRNA comprises a pair of sense and antisense sequences selected from any of the pairs in Tables 5-1, 5-2, and 5-3.
[0570] In some embodiments, the dsRNA comprises a pair of sense and antisense sequences selected from any of the pairs in Table 5-1.
[0571] In some embodiments, the dsRNA comprises a pair of sense and antisense sequences selected from any of the pairs in Table 5-2.
[0572] In a third aspect, the present invention provides a double-stranded nucleotide (dsRNA) for inhibiting the expression of apolipoprotein C3 (APOC3) in cells, said dsRNA comprising a sense strand and an antisense strand forming a double-stranded region, wherein the length of said sense strand and said antisense strand is each independently 15-30 nucleotides, and said antisense strand comprises at least 15 consecutive nucleotide sequences that differ from one of the antisense strand sequences listed in Table 1 by 0, 1, 2 or 3 nucleotides. In some embodiments, the antisense strand comprises at least 15 consecutive nucleotide sequences that differ from SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:78, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, and SEQ ID NO:98 by 0, 1, 2, or 3 nucleotides.
[0573] In some embodiments, the positive strand comprises at least 15 consecutive nucleotide sequences that differ from one of the positive strand sequences listed in Table 1 by 0, 1, 2, or 3 nucleotides.
[0574] In some embodiments, the positive chain comprises at least 15 consecutive nucleotide sequences that differ from SEQ ID NO:14, SEQ ID NO:20, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51 by 0, 1, 2, or 3 nucleotides.
[0575] In some implementations, the dsRNA is siRNA.
[0576] In some embodiments, the length of the double-stranded region is 15-25 nucleotide pairs, preferably 16-23 nucleotide pairs, and more preferably 19-21 nucleotide pairs.
[0577] In some embodiments, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang of at least one nucleotide; for example, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having at least two nucleotides. In some specific embodiments, the overhang is selected from U, UU, UUU, AA, AG, GG, and UA. In other specific embodiments, the overhang is selected from U, UU, UUU, and AA.
[0578] In some embodiments, the antisense strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences of any antisense strand sequence listed in Table 1. In some preferred embodiments, the antisense strand comprises any antisense strand sequence listed in Table 1.
[0579] In some embodiments, the antisense strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences of any one of the antisense sequences from SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:78, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, and SEQ ID NO:98.
[0580] In other embodiments, the antisense strand comprises at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences of any of the antisense sequences in SEQ ID NO:90 and SEQ ID NO:95.
[0581] In some embodiments, the antisense strand comprises the nucleotide sequence shown in SEQ ID NO:1002 or SEQ ID NO:1003.
[0582] In other embodiments, the antisense strand comprises the nucleotide sequence shown in SEQ ID NO:1004 or SEQ ID NO:1005.
[0583] In other embodiments, the antisense strand comprises the nucleotide sequence shown in SEQ ID NO:1006, SEQ ID NO:1007, SEQ ID NO:1008, SEQ ID NO:1009, or SEQ ID NO:1010.
[0584] In other embodiments, the antisense strand comprises the nucleotide sequence shown in SEQ ID NO:90 or SEQ ID NO:95.
[0585] In some embodiments, the positive strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, or at least 21 consecutive nucleotide sequences of any positive strand sequence listed in Table 1. In some preferred embodiments, the positive strand comprises any positive strand sequence listed in Table 1.
[0586] In some embodiments, the positive strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences of any one of the antisense sequences of SEQ ID NO:14, SEQ ID NO:20, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51.
[0587] In other embodiments, the positive strand comprises at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences of any of the positive sequences in SEQ ID NO:43 and SEQ ID NO:48.
[0588] In some embodiments, the positive strand comprises the nucleotide sequence shown in SEQ ID NO:1011, SEQ ID NO:1012 or SEQ ID NO:1013.
[0589] In other embodiments, the positive strand comprises the nucleotide sequence shown in SEQ ID NO:1014 or SEQ ID NO:1015.
[0590] In other embodiments, the positive strand comprises the nucleotide sequence shown in SEQ ID NO:1016, SEQ ID NO:1017, SEQ ID NO:1018, SEQ ID NO:1019, SEQ ID NO:1020, or SEQ ID NO:1021.
[0591] In other embodiments, the positive strand comprises the nucleotide sequence shown in SEQ ID NO:43 or SEQ ID NO:48.
[0592] In some embodiments, the dsRNA comprises any of the following pairs of paired sense and antisense sequences:
[0593] (1): Justice chain: SEQ ID NO:14, Antisense chain: SEQ ID NO:61;
[0594] (2): Justice chain: SEQ ID NO:20, Antisense chain: SEQ ID NO:67;
[0595] (3): Justice chain: SEQ ID NO:26, Antisense chain: SEQ ID NO:73;
[0596] (4): Justice chain: SEQ ID NO:28, Antisense chain: SEQ ID NO:75;
[0597] (5): Justice chain: SEQ ID NO:31, Antisense chain: SEQ ID NO:78;
[0598] (6): Justice chain: SEQ ID NO:39, Antisense chain: SEQ ID NO:86;
[0599] (7): Justice chain: SEQ ID NO:40, Antisense chain: SEQ ID NO:87;
[0600] (8): Justice chain: SEQ ID NO:41, Antisense chain: SEQ ID NO:88;
[0601] (9): Justice chain: SEQ ID NO:42, Antisense chain: SEQ ID NO:89;
[0602] (10): Justice chain: SEQ ID NO:43, Antisense chain: SEQ ID NO:90;
[0603] (11): Justice chain: SEQ ID NO:44, Antisense chain: SEQ ID NO:91;
[0604] (12): Justice chain: SEQ ID NO:45, Antisense chain: SEQ ID NO:92;
[0605] (13): Justice chain: SEQ ID NO:46, Antisense chain: SEQ ID NO:93;
[0606] (14: Justice Chain: SEQ ID NO:47, Antisense Chain: SEQ ID NO:94;
[0607] (15): Justice chain: SEQ ID NO:48, Antisense chain: SEQ ID NO:95;
[0608] (16): Justice chain: SEQ ID NO:49, Antisense chain: SEQ ID NO:96;
[0609] (17): Justice chain: SEQ ID NO:50, Antisense chain: SEQ ID NO:97;
[0610] (18): Justice chain: SEQ ID NO:51, Antisense chain: SEQ ID NO:98.
[0611] In some embodiments, substantially all nucleotides of the sense strand and substantially all nucleotides of the antisense strand are modified nucleotides. In other embodiments, all nucleotides of the sense strand and all nucleotides of the antisense strand are modified nucleotides.
[0612] In some embodiments, the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of: 2'-O-methyl modification, 2'-fluoro modification, 2'-O-methoxyethyl (MOE) modification, 2'-deoxynucleotide, unlocked nucleic acid nucleotide (UNA), glycol nuclec acid nucleotide (GNA), (E)-vinylphosphonate nucleotide, reverse nucleotide, reverse abase-free nucleotide, and phosphate thioester nucleotides with inter-nucleotide bonds.
[0613] In some embodiments, the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of: 2'-O-methyl modification, 2'-fluoro modification, 2'-O-methoxyethyl (MOE) modification, 2'-deoxynucleotide, unlocked nucleic acid nucleotide (UNA), glycol nuclec acid nucleotide (GNA), reverse nucleotide, reverse abase-free nucleotide, and modifications involving inter-nucleotide thiophosphate bonds.
[0614] In some implementations, the antisense strand is 19, 20, 21, 22, or 23 nucleotides in length.
[0615] In some implementations, the positive chain is 19, 20, or 21 nucleotides in length.
[0616] In some embodiments, the antisense strand is 21, 22, or 23 nucleotides long, and the sense strand is 19, 20, or 21 nucleotides long.
[0617] In some implementations, the antisense strand is 23 nucleotides long and the sense strand is 21 nucleotides long.
[0618] In some embodiments, the antisense strand has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1.
[0619] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 14, and 16.
[0620] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 6, 14, and 16.
[0621] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 6, 8, 9, 14, and 16.
[0622] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 2, 4, 6, 8, 10, 14, 16, 18.
[0623] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 2, 4, 6, 12, 14, 16, 18, 20.
[0624] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 14, and 16.
[0625] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 9, 14, and 16.
[0626] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 14, and 16.
[0627] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 12, 14, and 16.
[0628] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 14, 16, 20.
[0629] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 1, 2, 9, 14, 16.
[0630] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 1, 2, 10, 14, 16.
[0631] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 9, 10, 14, and 16.
[0632] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 9, 10, 14, and 16.
[0633] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 1, 2, 12, 14, 16.
[0634] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 12, 16.
[0635] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 2, 6, 7, 8, 9, 14, 16.
[0636] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 12, 14, and 16. In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 3, 10, 14, and 16.
[0637] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 4, 10, 14, and 16.
[0638] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 6, 10, 14, and 16.
[0639] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 8, 10, 14, and 16.
[0640] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 14, 16, and 18.
[0641] In some embodiments, the antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 14, 16, 20.
[0642] In some implementations, the antisense strand has 1, 2, or 3 2'-deoxynucleotides (DNA).
[0643] In some embodiments, the antisense strand has one 2'-deoxynucleotide (DNA) and is located at position 12, 14, or 15 (counting from the 5' end). In some preferred embodiments, the antisense strand has one 2'-deoxynucleotide (DNA) and is located at position 15 (counting from the 5' end).
[0644] In some embodiments, the antisense strand has one, two, or three nucleotides modified with 2'-O-methoxyethyl (MOE).
[0645] In some embodiments, the antisense strand has one 2'-O-methoxyethyl (MOE) modified nucleotide and is located at position 9 or 10 (counting from the 5' end).
[0646] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 9 and 10 (counting from the 5' end).
[0647] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 3 and 15 (counting from the 5' end).
[0648] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 3 and 20 (counting from the 5' end).
[0649] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 3 and 21 (counting from the 5' end).
[0650] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 5 and 15 (counting from the 5' end).
[0651] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 5 and 20 (counting from the 5' end).
[0652] In some embodiments, the antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 5 and 21 (counting from the 5' end).
[0653] In some embodiments, the antisense strand has 1-4 phosphate thioester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23.
[0654] In some embodiments, the antisense strand has phosphate ester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23.
[0655] In some embodiments, the antisense strand has a 2'-fluoro-modified nucleotide at position 1 (counting from the 5' end) and two 2'-O-methoxyethyl (MOE)-modified nucleotides at positions 5 and 15 (counting from the 5' end).
[0656] In some embodiments, the antisense strand has a 2'-fluorinated nucleotide at position 1 (counting from the 5' end) and a 2'-deoxynucleotide (DNA) at position 15 (counting from the 5' end).
[0657] In some embodiments, the antisense strand has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1, (counting from the 5' end) two 2'-O-methoxyethyl (MOE) nucleotides at positions 5 and 15, and (counting from the 5' end) one 2'-deoxynucleotide (DNA) at position 15.
[0658] In some embodiments, the antisense strand has five 2'-fluoromodified nucleotides (counting from the 5' end) at positions 1, 2, 10, 14, and 16, and two 2'-O-methoxyethyl (MOE) modified nucleotides (counting from the 5' end) at positions 5 and 15.
[0659] In some embodiments, the antisense strand has five 2'-fluoromodified nucleotides (counting from the 5' end) at positions 2, 10, 12, 14, and 16, and two 2'-O-methoxyethyl (MOE) modified nucleotides (counting from the 5' end) at positions 5 and 15.
[0660] In some embodiments, the antisense strand has five 2'-fluorinated nucleotides (counted from the 5' end) at positions 1, 2, 10, 14, and 16, and one 2'-deoxynucleotide (DNA) at position 15 (counted from the 5' end).
[0661] In some embodiments, the antisense strand has five 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 10, 14, and 16, two 2'-O-methoxyethyl (MOE) nucleotides (counting from the 5' end) at positions 5 and 15, and one 2'-deoxynucleotide (DNA) at position 15 (counting from the 5' end).
[0662] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0663] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0664] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0665] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0666] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 6, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0667] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0668] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0669] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 6, 8, 9, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 7, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0670] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0671] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0672] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 4, 6, 8, 10, 14, 16, and 18, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 5, 7, 9, 11, 12, 13, 15, 17, 19, 20, 21, 22, and 23; and / or
[0673] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0674] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0675] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 4, 6, 12, 14, 16, 18, and 20, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 5, 7, 8, 9, 10, 11, 13, 15, 17, 19, 21, 22, and 23; and / or
[0676] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0677] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0678] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 14, and 16, and nucleotides with 2'-O-methyl modification at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0679] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0680] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0681] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 9, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0682] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0683] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0684] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0685] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0686] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0687] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 12, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0688] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0689] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0690] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 14, 16, and 20, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or
[0691] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0692] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0693] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 9, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0694] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0695] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0696] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0697] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0698] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0699] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 9, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0700] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0701] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0702] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 9, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0703] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0704] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0705] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 12, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0706] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0707] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0708] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 12, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at position 9; and nucleotides with 2'-O-methyl modification at positions 3, 4, 5, 6, 7, 8, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0709] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0710] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0711] (i) (counting from the 5' end) 2'-fluoro modified nucleotides at positions 1, 2, 12, 14, and 16; 2'-O-methoxyethyl modified nucleotide at position 10; and 2'-O-methyl modified nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0712] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0713] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0714] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 12, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 9 and 10; and nucleotides with 2'-O-methyl modification at positions 3, 4, 5, 6, 7, 8, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0715] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0716] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0717] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 3 and 15; and nucleotides with 2'-O-methyl modification at positions 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0718] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0719] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0720] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 3, 4, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0721] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0722] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0723] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0724] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0725] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0726] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 14, and 16; 2'-deoxynucleotides (DNA) at position 12; and 2'-O-methylated nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0727] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0728] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0729] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 12, and 16; 2'-deoxynucleotides (DNA) at position 14; and 2'-O-methyl nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0730] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0731] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0732] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 12, 14, and 16; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methylated nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0733] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0734] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0735] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 10, 14, and 16; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methylated nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0736] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0737] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0738] (i) (counting from the 5' end) 2'-fluoro-modified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl-modified nucleotides at positions 3 and 20; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl-modified nucleotides at positions 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or
[0739] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0740] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0741] (i) (counting from the 5' end) 2'-fluoro-modified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl-modified nucleotides at positions 3 and 21; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl-modified nucleotides at positions 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 22, and 23; and / or
[0742] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0743] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0744] (i) (counting from the 5' end) 2'-fluoromodified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl modified nucleotides at positions 5 and 20; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl modified nucleotides at positions 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or
[0745] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0746] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0747] (i) (counting from the 5' end) 2'-fluoromodified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl modified nucleotides at positions 5 and 21; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl modified nucleotides at positions 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 22, and 23; and / or
[0748] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0749] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0750] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 10, 12, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0751] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0752] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0753] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 12, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0754] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0755] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0756] (i) (counting from the 5' end) nucleotides with 2'-fluoro modification at positions 2, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0757] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0758] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0759] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 3, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 4, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0760] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0761] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0762] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 3, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0763] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0764] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0765] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 4, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0766] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0767] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0768] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 4, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0769] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0770] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0771] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 5, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0772] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0773] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0774] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 6, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0775] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0776] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0777] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 6, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0778] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0779] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0780] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 8, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or
[0781] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0782] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0783] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 8, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or
[0784] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0785] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0786] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 10, 14, 16, and 18; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 17, 19, 20, 21, 22, and 23; and / or
[0787] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0788] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0789] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 14, 16, and 18, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 19, 20, 21, 22, and 23; and / or
[0790] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0791] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0792] (i) (counting from the 5' end) nucleotides with 2'-fluoro modification at positions 2, 10, 14, 16, and 20; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 21, 22, and 23; and / or
[0793] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0794] In some embodiments, the antisense strand has a length of 23 nucleotides and has
[0795] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 14, 16, and 20, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or
[0796] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23.
[0797] In some implementations, the positive chain has a length of 19, 20, or 21 nucleotides.
[0798] In some embodiments, the positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 13 and 15.
[0799] In some embodiments, the positive strand has 2'-fluorinated nucleotides (counting from the 5' end) located at positions 9, 10, 11, and 13.
[0800] In some embodiments, the positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11 and 15.
[0801] In some embodiments, the positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13, and 15.
[0802] In some embodiments, the positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 11, 13 and 15.
[0803] In some implementations, the positive strand has 1, 2, or 3 2'-deoxynucleotides (DNA).
[0804] In some implementations, the positive strand has 1, 2 or 3 2'-deoxynucleotides (DNA), one of which is located at position 20 (counting from the 5' end).
[0805] In some implementations, the positive strand has 1, 2, or 3 2'-deoxynucleotides (DNA), and one of them is located at position 1, 2, 3, or 4 (counting from the 5' end).
[0806] In some implementations, the positive strand has one 2'-deoxynucleotide (DNA), and one of them is located at position 3 or 4 (counting from the 5' end).
[0807] In some implementations, the positive strand has one 2'-deoxynucleotide (DNA), and one of them is located at position 3 (counting from the 5' end).
[0808] In some implementations, the positive strand has one 2'-deoxynucleotide (DNA), and one of them is located at position 4 (counting from the 5' end).
[0809] In some embodiments, the positive strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 13 and 15, and one 2'-deoxynucleotide (DNA) at position 3 or 4 (counting from the 5' end).
[0810] In some implementations, the positive strand has one 2'-deoxynucleotide (DNA) and is located at position 7, 10, or 20 (counting from the 5' end).
[0811] In some implementations, the positive strand has two 2'-deoxynucleotides (DNA), one of which is located at position 1, 2, 3 or 4 (counting from the 5' end), and the other is located at position 20 (counting from the 5' end).
[0812] In some implementations, the positive strand has 1, 2, or 3 unlocked nucleic acid nucleotides (UNA).
[0813] In some embodiments, the positive strand has 1-4 phosphate thioester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21.
[0814] In some embodiments, the positive strand has phosphate ester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0815] In some embodiments, the positive strand has a length of 21 nucleotides and has
[0816] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 9, 10, 11, and 13, and nucleotides with 2'-O-methyl modifications at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20, and 21; and / or
[0817] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0818] In some embodiments, the positive strand has a length of 21 nucleotides and has
[0819] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 9, 10, 11, and 15, and nucleotides with 2'-O-methyl modifications at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 13, 14, 16, 17, 18, 19, 20, and 21; and / or
[0820] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0821] In some embodiments, the positive strand has a length of 21 nucleotides and has
[0822] (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 9, 10, 11, 13, and 15, and nucleotides with 2'-O-methyl modifications at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 16, 17, 18, 19, 20, and 21; and / or
[0823] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0824] In some embodiments, the positive strand has a length of 21 nucleotides and has
[0825] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13, and 15; 2'-deoxynucleotides (DNA) at position 4; and 2'-O-methyl nucleotides at positions 1, 2, 3, 5, 6, 7, 8, 12, 14, 16, 17, 18, 19, 20, and 21; and / or
[0826] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0827] In some embodiments, the positive strand has a length of 21 nucleotides and has
[0828] (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13, and 15; 2'-deoxynucleotides (DNA) at position 3; and 2'-O-methyl nucleotides at positions 1, 2, 4, 5, 6, 7, 8, 12, 14, 16, 17, 18, 19, 20, and 21; and / or
[0829] (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3.
[0830] In some embodiments, the antisense strand has a length of 23 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1 and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) 2'-fluorinated nucleotides at positions 13 and 15.
[0831] In some embodiments, the antisense strand has a length of 23 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1 and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at positions 13 and 15 and a 2'-deoxynucleotide (DNA) at position 3.
[0832] In some embodiments, the antisense strand has a length of 23 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at positions 13 and 15, and a 2'-deoxynucleotide (DNA) at position 4.
[0833] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end) and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end).
[0834] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end), and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end), and 2'-deoxynucleotide (DNA) at position 3.
[0835] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end), and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end), and 2'-deoxynucleotide (DNA) at position 4.
[0836] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 12, 14, and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 13 and 15, and 2'-deoxynucleotide (DNA) at position 4.
[0837] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 12, 14, and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 13 and 15, and 2'-deoxynucleotide (DNA) at position 3.
[0838] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 12, 14 and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 13 and 15.
[0839] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 10, 14 and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 9, 10, 11, 13 and 15.
[0840] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 1, 2, 10, 14 and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 9, 10, 11, 13 and 15, and 2'-deoxynucleotide (DNA) at position 3.
[0841] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 1, 2, 10, 14 and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 9, 10, 11, 13 and 15, and 2'-deoxynucleotide (DNA) at position 4.
[0842] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 12, 14, and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 9, 10, 11, 13, and 15, and 2'-deoxynucleotide (DNA) at position 4.
[0843] In some embodiments, the antisense strand has a length of 23 nucleotides and has (counting from the 5' end) 2'-fluorinated nucleotides at positions 2, 10, 12, 14, and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13, and 15, and 2'-deoxynucleotide (DNA) at position 3.
[0844] In some embodiments, the antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 12, 14, and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counting from the 5' end) at positions 9, 10, 11, 13, and 15.
[0845] In some embodiments, the first nucleotide at the 5' end of the antisense strand is selected from the following structures:
[0846] Where Base is a base A, U, G, C, T or other nucleotide bases, and R is H, methoxy, F or methoxyethoxy.
[0847] In some embodiments, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide.
[0848] In some implementations, the antisense chain comprises an antisense chain sequence selected from any of the items shown in Table 4.
[0849] In some implementations, the justice chain comprises a sequence of justice chains selected from any of the tables shown in Table 2 or Table 3.
[0850] In some embodiments, the dsRNA comprises a pair of sense and antisense sequences selected from any of the pairs in Tables 5-1, 5-2, and 5-3.
[0851] In some embodiments, the dsRNA is further conjugated to a ligand moiety comprising N-acetylgalactosamine, preferably with the 3' end of the positive strand conjugated to the ligand moiety.
[0852] In some embodiments, the ligand has the following structure:
[0853] This indicates the position where the ligand is attached to the positive strand of the dsRNA via a phosphate ester group or a thiophosphate ester group. In some embodiments, the ligand is selected from the group consisting of formulas II to XXXI:
[0854] Where Y is either O or S and n is an integer between 3 and 6 (Equation XXIV)
[0855] Where Y is either O or S and n is an integer from 3 to 6 (equation XXV)
[0856] Where X is O or S (Equation XXVII)
[0857] This indicates the position where the dsRNA is attached to the positive strand via a phosphate group or a thiophosphate group.
[0858] In some embodiments, the ligand is selected from the following structures:
[0859] This indicates the linking bond between the ligand and dsRNA or siRNA.
[0860] In some embodiments, the dsRNA is coupled to the ligand as shown below.
[0861] Where X is O or S, and in some implementations, X is O.
[0862] In some implementations, the dsRNA is any of the modified siRNAs shown in Tables 5-1, 5-2, and 5-3.
[0863] In a fourth aspect, the present invention provides a vector comprising a nucleotide sequence encoding the dsRNA of the present invention.
[0864] In a fifth aspect, the present invention provides a cell containing the dsRNA or vector of the present invention.
[0865] In a sixth aspect, the present invention provides pharmaceutical compositions comprising the dsRNA, vector or cell of the present invention, and optionally a pharmaceutically acceptable carrier or excipient.
[0866] In a seventh aspect, the present invention provides a kit comprising the dsRNA, vector, or cells of the present invention.
[0867] In an eighth aspect, the present invention provides a method for reducing apolipoprotein C3 (APOC3) in a subject, the method comprising administering to the subject an effective amount of the dsRNA, vector, cell, or pharmaceutical composition described in the present invention.
[0868] In a ninth aspect, the present invention provides the use of the dsRNA, vector, cell, or pharmaceutical composition described herein in the preparation of a medicament that reduces apolipoprotein C3 (APOC3) in a subject.
[0869] In a tenth aspect, the dsRNA, vector, cell, or pharmaceutical composition described in this invention is used to reduce apolipoprotein C3 (APOC3) in a subject.
[0870] In an eleventh aspect, the present invention also provides a method for treating a disease or condition in a subject that benefits from reduced expression of apolipoprotein C3 (APOC3), the method comprising the step of administering an effective amount of the dsRNA, vector, cell, or pharmaceutical composition of the present invention to the subject.
[0871] In a twelfth aspect, the present invention provides the use of the dsRNA, vector, cell, or pharmaceutical composition thereof in the preparation of a medicament for treating a disease or condition in which a subject benefits from reduced expression of apolipoprotein C3 (APOC3).
[0872] In a thirteenth aspect, the dsRNA, vector, cell, or pharmaceutical composition described in this invention is used to treat diseases or conditions in subjects that benefit from reduced expression of apolipoprotein C3 (APOC3).
[0873] In a fourteenth aspect, the present invention provides a method for preventing at least one symptom in a subject suffering from a disease or condition that benefits from reduced expression of apolipoprotein C3 (APOC3), the method comprising the step of administering to the subject an effective amount of the dsRNA, vector, cell, or pharmaceutical composition of the present invention.
[0874] In a fifteenth aspect, the present invention provides the use of the dsRNA, vector, cell, or pharmaceutical composition thereof in the preparation of a medicament for preventing at least one symptom in a subject suffering from a disease or condition that benefits from reduced expression of apolipoprotein C3 (APOC3).
[0875] In a sixteenth aspect, the dsRNA, vector, cell, or pharmaceutical composition of the present invention is used to prevent at least one symptom in a subject suffering from a disease or condition that benefits from reduced expression of apolipoprotein C3 (APOC3).
[0876] In some implementations, the disease or condition that benefits from reduced apolipoprotein C3 (APOC3) expression is an APOC3-mediated or APOC3-related disease.
[0877] In some implementations, the APOC3-mediated or APOC3-related diseases are selected from the group consisting of: hyperlipidemia, hypertriglyceridemia, stroke, atherosclerosis, thrombosis, coronary heart disease, aortic stenosis, severe hypertriglyceridemia (sHTG), or familial chylomicronemia syndrome (FCS).
[0878] In some embodiments, the methods of the present invention for treating a disease or condition in which apolipoprotein C3 (APOC3) expression is reduced, for preventing at least one symptom in a subject suffering from a disease or condition in which apolipoprotein C3 (APOC3) expression is reduced, or for reducing apolipoprotein C3 (APOC3) in a subject include subcutaneous, topical, or intravenous administration of the dsRNA, vector, cell, or pharmaceutical composition to the subject.
[0879] In some implementations, the subjects are humans.
[0880] Invention Details
[0881] In this specification and claims, unless otherwise expressly stated herein, the singular forms “a,” “one,” and “this” include the plural forms.
[0882] When numerical ranges are given in the implementation scheme, it should be understood that, unless otherwise stated in this invention, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art. In addition to the specific methods, devices, and materials used in the embodiments, based on the prior art mastery of one of ordinary skill in the art and the description of this invention, any prior art methods, devices, and materials similar to or equivalent to those described, used, and materials in the embodiments of this invention may be used to implement this invention, and all such methods, devices, and materials fall within the protection scope of this invention. The embodiments of this invention are described in more detail below.
[0883] Definitions and Explanations
[0884] As used herein, the terms “comprising,” “including,” “having,” or “containing” are open-ended expressions that include the contents specified in this disclosure but do not exclude other contents.
[0885] In this paper, a “double-stranded region” refers to a region containing two antiparallel and complementary or substantially complementary nucleic acid strands.
[0886] As used herein, the term "double-stranded RNA" or "dsRNA" refers to a ribonucleic acid molecule or ribonucleic acid molecule complex containing the double-stranded region as defined above. The two parts forming the double-stranded region can be two distinct parts of a larger RNA molecule, or they can be separate RNA molecules.
[0887] When the two parts are separate RNA molecules, the dsRNA in this article is referred to as small interfering RNA or short interfering RNA, or simply siRNA.
[0888] When two parts are two distinct portions of a larger molecule, i.e., when the 3' end of one part is linked to the 5' end of the other part to form a double-stranded region by one or more uninterrupted nucleotides, the uninterrupted nucleotide used for the linkage is called a "hairpin loop." When the two parts are covalently linked to form a double-stranded region by a method other than a hairpin loop, the linkage structure is called a "linkosome." After such dsRNA is introduced into the cell, it is cleaved into siRNA by an intracellular endonuclease called Dicer.
[0889] The term "siRNA" in this article refers to a class of double-stranded RNA molecules comprising a sense strand and an antisense strand, which can mediate the silencing of target RNAs (e.g., mRNAs, such as transcripts of genes encoding proteins) that are complementary or substantially complementary to the antisense strand. siRNAs are typically double-stranded, consisting of an antisense strand complementary to the target RNA and a sense strand complementary or substantially complementary to that antisense strand. For convenience, such mRNAs are also referred to herein as mRNAs to be silenced. Such genes are also referred to as target genes. Typically, the RNA to be silenced is an endogenous gene or a pathogen gene. Additionally, RNAs other than mRNAs (e.g., tRNAs) and viral RNAs can also be targeted.
[0890] As used herein, the term "antisense strand" refers to a strand in dsRNA (especially siRNA) that contains regions that are fully or substantially complementary to the target sequence.
[0891] As used herein, the term "complementary region" refers to a region on the antisense strand that is perfectly or substantially complementary to the target mRNA sequence. In cases where the complementary region is not perfectly complementary to the target sequence, mismatches can occur within the molecule or at the ends. Typically, the most tolerant mismatches are located in the end regions, for example, within 5, 4, 3, 2, or 1 nucleotides at the 5' and / or 3' ends. The portion of the antisense strand most sensitive to mismatches is called the "seed region." For example, in a siRNA containing a 19-nt strand, the 19th position (from 5' to 3') can tolerate some mismatches.
[0892] When used in this context, the term "complementarity" refers to the ability of a first polynucleotide to hybridize with a second polynucleotide under certain conditions, such as stringent conditions. For example, stringent conditions may include 400 mM NaCl, 40 mM PIPES at pH 6.4, and 1 mM EDTA at 50 or 70°C for 12–16 hours.
[0893] As used herein, in order to satisfy the above requirements regarding their hybridization ability, "complementary" sequences may also include base pairs formed entirely from non-Watson-Crick base pairs and / or from non-natural and modified nucleotides. Such non-Watson-Crick base pairs include, but are not limited to, G:U swing base pairs or Hoogstein base pairs.
[0894] As used herein, a polynucleotide that is “at least partially complementary” or “substantially complementary” to messenger RNA (mRNA) means a polynucleotide that is substantially complementary to a continuous portion of the mRNA of interest (e.g., the mRNA encoding APOC3). For example, a polynucleotide is at least partially complementary to the APOC3 mRNA if the sequence is substantially complementary to an uninterrupted portion of the APOC3 mRNA.
[0895] The terms “complementary,” “fully complementary,” and “substantially complementary” as used herein can be used relative to the base pairing between the sense and antisense strands of dsRNA, particularly siRNA, or between the antisense strand of dsRNA, particularly siRNA, and the target sequence.
[0896] As used herein, the term "sense chain" refers to a chain of siRNA that includes regions substantially complementary to the regions defined herein as antisense chains.
[0897] "Nucleoside" is a compound composed of two substances: a purine or pyrimidine base and ribose or deoxyribose. "Nucleotide" is a compound composed of three substances: a purine or pyrimidine base, ribose or deoxyribose, and phosphate. "Oligonucleotide" refers to nucleic acid molecules (RNA or DNA) with a length of less than 100, 200, 300, or 400 nucleotides.
[0898] A "base" is the basic building block for the synthesis of nucleosides, nucleotides, and nucleic acids. Its constituent elements include nitrogen, hence it is also called a "nitrogenous base." In this article, unless otherwise specified, the capital letters A, U, T, G, and C represent the base composition of nucleotides, namely adenine, uracil, thymine, guanine, and cytosine, respectively.
[0899] In this invention, "other nucleotide bases" (also referred to as "other nucleobases" or "modified nucleobases") refer to nitrogen-containing heterocyclic compounds other than adenine (A), uracil (U), guanine (G), cytosine (C), and thymine (T), which can participate in base pairing in the siRNA double-stranded structure or be used to enhance the in vivo and in vitro stability of siRNA, reduce immunogenicity, and improve target binding affinity and specificity. Examples include, but are not limited to:
[0900] (a) Naturally occurring RNA modification bases, such as, but not limited to: pseudouracil (Ψ), 5-methylcytosine (m 5 C), N 6 -Methyladenine (N 6 -Methyladenosine,m 6 A) Inosine (I), Dihydrouridine (D), 7-Methylguanosine (m) 7 G) etc.;
[0901] (ii) Chemically modified base analogs for siRNA, such as, but not limited to:
[0902] Halogenated pyrimidines: 5-fluorouracil (5-FU), 5-bromouracil (5-BrU), 5-iodouracil (5-IU);
[0903] Thiopyrimidines: 2-Thiouracil, 4-Thiouracil;
[0904] Alkyne-modified pyrimidines: 5-Propynyluracil, 5-Propynylcytosine;
[0905] Aminopurines: 2-Aminopurine, 2,6-Diaminopurine;
[0906] Deazapurines: 7-Deazaadenine, 7-Deazaguanine, 8-Azaguanine;
[0907] Isobasic bases: isocytosine, isoguanine, etc.;
[0908] (iii) Universal bases, such as but not limited to: 5-nitroindole, 3-nitropyrrole, difluorotoluyl and its derivatives, are used to reduce the off-target effect of siRNA or enhance the sequence fault pairing capability.
[0909] The aforementioned "other nucleotide bases" can be linked to ribose via N-glycosidic bonds (or C-glycosidic bonds, such as pseudouracil) to form corresponding modified nucleosides, which can then be further phosphorylated to form modified nucleotides that are incorporated into the sense and / or antisense strands of siRNA.
[0910] As used herein, the term "nucleotide overhang" refers to at least one unpaired nucleotide that protrudes from the double-stranded region of siRNA. A nucleotide overhang exists, for example, when the 3' end of one strand of siRNA extends beyond the 5' end of the other strand, or vice versa. siRNA may contain overhangs having at least one nucleotide, at least two nucleotides, at least three nucleotides, at least four nucleotides, or at least five or more nucleotides. A nucleotide overhang may contain or consist of nucleotides / modified nucleotides (including deoxynucleotides / nucleosides). One or more overhangs may be located on the sense or antisense strand, or any combination thereof. An overhang having one or more nucleotides may be present at the 5' end, 3' end, or both ends of the antisense or sense strand of siRNA.
[0911] "Flat-ended" or "blunt-ended" means that there are no unpaired nucleotides at that end of the double-stranded siRNA, i.e., no nucleotide overhangs. "Flat-ended siRNA" is a double-stranded siRNA that is double-stranded along its entire length, meaning that there are no nucleotide overhangs at either end of the molecule.
[0912] The dsRNA (especially siRNA) of the present invention comprises substantially all modified nucleotides. For example, substantially all nucleotides of the sense strand are modified nucleotides, or substantially all nucleotides of the antisense strand are modified nucleotides, or substantially all nucleotides of both the sense and antisense strands are modified nucleotides. In other embodiments of the invention, all nucleotides of the dsRNA (especially siRNA) of the present invention are modified nucleotides. For example, substantially all nucleotides of the sense strand are modified nucleotides, or substantially all nucleotides of the antisense strand are modified nucleotides, or substantially all nucleotides of both the sense and antisense strands are modified nucleotides. As used herein, “substantially all nucleotides are modified” means that the majority, but not all, nucleotides of the dsRNA (especially siRNA) of the present invention are modified, and may include no more than 5, 4, 3, 2, or 1 unmodified nucleotides.
[0913] In this invention, "modified nucleotide" or "nucleotide is modified" means independently having a modified sugar moiety, modified internucleotide bonding, or modified nucleic acid base, or any combination of the foregoing modifications. Therefore, the term "modified nucleotide" or "nucleotide is modified" encompasses the substitution, addition, or removal of, for example, functional groups or atoms, in internucleotide bonding, sugar moiety, or nucleic acid bases. Modifications applicable to this invention include all types of modifications disclosed herein or known in the art.
[0914] In some embodiments of the invention, including deoxyribonucleotides (if present) in dsRNA or siRNA may be considered as modified nucleotides or nucleotides that are modified.
[0915] In this invention, "substantially all nucleotides are modified nucleotides" means that all nucleotides in dsRNA or siRNA are modified, that is, there are no more than 5, 4, 3, 2 or 1 unmodified nucleotides in the strand of dsRNA or siRNA.
[0916] As used herein, "ligand" or "ligand moiety" refers to a chemical portion conjugated to dsRNA (especially siRNA) that can alter the distribution, targeting, or lifespan of the dsRNA (especially siRNA). In some embodiments, the ligand moiety provides enhanced affinity for selected targets (e.g., molecules, cells or cell types, compartments, e.g., cellular or organ compartments, tissues, organs, or body regions) compared to siRNA, for example, in the absence of this ligand moiety. In some embodiments, the ligand moiety targets the desialyl glycoprotein receptor (ASGPR) on hepatocytes. Binding of the ligand moiety to ASGPR mediates the internalization of vesicles coated with clathrin. Maturation of the endosome leads to a decrease in the pH of the lysosome, which promotes the dissociation of the ligand-receptor complex, thereby releasing the dsRNA (especially siRNA). Conjugation of the ligand moiety targeting the desialyl glycoprotein receptor (ASGPR) on hepatocytes results in the efficacy and stability of the dsRNA (especially siRNA) in vivo or within cells. This is advantageous for subcutaneous administration of the dsRNA (especially siRNA).
[0917] In some embodiments, the "ligand" or "ligand moiety" is a glycoconjugate comprising one or more GalNAc derivatives. The GalNAc derivatives can be attached via divalent, trivalent, or tetravalent branching connectors. In some embodiments, the "ligand" or "ligand moiety" is conjugated to the 3' end of the positive chain.
[0918] In some embodiments, the carbohydrate conjugates used in this invention are selected from the group consisting of:
[0919] Where Y is either O or S and n is an integer between 3 and 6 (Equation XXIV)
[0920] Where Y is either O or S and n is an integer from 3 to 6 (equation XXV)
[0921] Where X is O or S (Equation XXVII)
[0922] In some implementations, "ligand" or "ligand portion" is selected from the following structures:
[0923] This indicates the linking bond between the ligand and dsRNA or siRNA.
[0924] As used herein, the term “inhibition” is used interchangeably with “reduction,” “silence,” “downregulation,” and other similar terms, and includes any level of inhibition.
[0925] As used herein, the term "vector" refers to a nucleic acid molecule capable of amplifying or expressing another nucleic acid linked to it. In this context, "vector" generally refers to a vector that can autonomously replicate within a host cell, preferably a multi-copy vector. Furthermore, vectors typically possess markers such as antibiotic resistance genes for selecting transformants. Additionally, vectors may have promoters and / or terminators for expressing the introduced gene. Vectors can be, for example, vectors derived from bacterial plasmids, viral vectors, vectors derived from yeast plasmids, vectors derived from bacteriophages, granules, phage particles, etc.
[0926] As used herein, the terms “treatment,” “management,” etc., refer to the administration of a drug or the performance of a procedure to achieve an effect. These effects may be preventative in terms of the complete or partial prevention of a disease or its symptoms, and / or therapeutic in terms of the partial or complete cure of a disease and / or its symptoms. As used herein, “treatment” may include treating a disease or condition (e.g., cancer) in mammals, particularly humans, and includes: (a) preventing the occurrence of the disease or its symptoms in subjects susceptible to the disease but not yet diagnosed with it (e.g., including diseases that may be related to or caused by the primary disease); (b) suppressing the disease, i.e., halting its development; and (c) alleviating the disease, i.e., causing its remission. Treatment may refer to any indication of success in treating or improving or preventing cancer, including any objective or subjective parameter, such as elimination; relief; reduction of symptoms or making the disease condition more tolerable for the patient; slowing the rate of deterioration or decline; or weakening the endpoint of deterioration. Treatment or improvement of symptoms is based on one or more objective or subjective parameters; including the results of a physician’s examination. Therefore, the term "treatment" includes the administration of the antibodies, compositions, or conjugates disclosed in this invention to prevent or delay, alleviate, stop, or inhibit the development of symptoms or conditions associated with a disease (e.g., cancer). The term "therapeutic effect" refers to the reduction, elimination, or prevention of disease, disease symptoms, or disease side effects in a subject.
[0927] The term "effective amount" as used in this invention refers to an amount sufficient to treat a disease when administered to a subject for the purpose of treating that disease.
[0928] As used herein, the term “subject” refers to any mammalian subject for diagnosis, treatment, or therapy. For therapeutic purposes, “mammal” means any animal classified as a mammal, including humans, livestock, and laboratory animals, zoo animals, sporting animals, or pet animals, such as dogs, horses, cats, cattle, sheep, goats, pigs, mice, rats, rabbits, guinea pigs, monkeys, etc.
[0929] sequence
[0930] The RNA sequence provided by this invention targets the APOC3 gene (or target gene, target mRNA sequence, target sequence). The target APOC3 mRNA sequence is shown in the gene with Genbank accession number NM_000040.3.
[0931] In this invention, the meanings of each abbreviation are as follows:
[0932] A, U, G, C, and T represent natural adenine ribonucleotide, uracil ribonucleotide, guanine ribonucleotide, cytosine ribonucleotide, and thymine ribonucleotide, respectively, and i represents hypoxanthine ribonucleotide.
[0933] (DNA) indicates that the nucleotide adjacent to it on the left is a deoxyribonucleotide. For example, A(DNA), T(DNA), G(DNA), and C(DNA) represent adenine deoxyribonucleotide, thymine deoxyribonucleotide, guanine deoxyribonucleotide, and cytosine deoxyribonucleotide, respectively.
[0934] m indicates that the nucleotide adjacent to it on the left is a nucleotide modified with 2'-OCH3. For example, Am, Um, Gm, Cm and im represent A, U, G, C and i modified with 2'-OCH3, respectively.
[0935] The 'f' indicates that the nucleotide adjacent to it on the left is a 2'-fluoro modified nucleotide. For example, Af, Uf, Gf, and Cf represent 2'-fluoro modified A, U, G, and C, respectively.
[0936] “s” indicates that the two adjacent nucleotides are linked by a phosphate thioester.
[0937] (UNA) indicates that the nucleotide adjacent to it on the left is an open cyclic nucleotide.
[0938] (GNA) indicates that the nucleotide adjacent to it on the left is ethylene glycol nucleic acid, A(GNA) represents adenosine-diol nucleic acid, C(GNA) represents cytidine-diol nucleic acid, and G(GNA) represents guanosine-diol nucleic acid.
[0939] (invAb) indicates a reverse debasing residue.
[0940] (MOE) indicates that the nucleotide to its left is a nucleotide modified with 2'-O-MOE.
[0941] 5-Me-C (MOE) represents the structure
[0942] eVP indicates that the nucleotide adjacent to it on its right is a (E)-vinyl phosphate modified nucleotide. For example, when the base is U, the structure of eVPUf is...
[0943] The carrier portion L96 has the following structure:
[0944] Table 1 shows the unmodified RNA sequences used in this invention.
[0945] Table 1. Nucleotide sequences of the sense and antisense strands of APOC3 mRNA.
[0946] Tables 2, 3, and 4 show the modified RNA sequences used in this invention.
[0947] Table 2. Sensitive strand sequences of modified siRNAs targeting APOC3 mRNA
[0948] Table 3. Sensitive strand sequences (linking ligands) of modified siRNAs targeting APOC3 mRNA.
[0949] Table 4. Modified siRNA antisense strand sequences targeting APOC3 mRNA
[0950] Tables 5-1, 5-2, and 5-3 show the paired siRNAs used in this invention.
[0951] Table 5-1 Paired siRNAs targeting APOC3 mRNA: sense and antisense strands
[0952] Table 5-2 Paired siRNAs targeting APOC3 mRNA: sense and antisense strands
[0953] Table 5-3 Paired siRNAs targeting APOC3 mRNA: sense and antisense strands Detailed Implementation
[0954] The present invention is further illustrated below by way of examples, but these examples do not limit the invention to the scope of the embodiments described. Experimental methods not specifically described in the following examples were performed according to conventional methods and conditions, or as selected according to the product instructions. The solvents and reference standards used in this invention are commercially available.
[0955] Example 1: Preparation of siRNA
[0956] Conventional nucleotide monomers can be obtained commercially, and nucleotides with eVP modification can be prepared commercially or by referring to methods known in the art, such as those disclosed in patents WO9213869 A1, WO2024098964 A1, and WO2016028649A1.
[0957] The siRNA of this invention was prepared using the solid-phase phosphoramide method well-known in the art. A brief description follows:
[0958] 1. Preparation of siRNA without ligand linkage
[0959] 1.1 Synthesis of the Chain of Justice
[0960] A solid-phase phosphoramide synthesis method was employed, using a blank CPG solid support as the starting cycle, to sequentially link nucleoside monomers according to the nucleotide arrangement of the positive strand. Each nucleoside monomer involved a four-step reaction process: deprotection, coupling, capping, and oxidation or thiolation. The synthetic scale was 1 μmol.
[0961] Commercially available phosphoramids with 2'-F, 2'-O-methyl, and other modifications were used. The nucleoside monomers were provided in 0.1 mol / L acetonitrile solution. Each reaction step was carried out at room temperature. Deprotection was performed three times using a 3% trichloroacetic acid-dichloromethane solution. The coupling reaction was activated twice using a 0.6 mol / L acetonitrile solution of 5-ethylthiotetrazole. Capping was performed twice using 10% acetic anhydride-acetonitrile and pyridine / N-methylimidazolium / acetonitrile (10:14:76, v / v / v). Oxidation was performed once using a 0.05 mol / L iodine / tetrahydrofuran / pyridine / water solution (70 / 20 / 10, v / v / v). Thiolation was performed once using a 0.2 mol / L pyridine solution of hydroflavin.
[0962] 1.2 Synthesis of Antisense Strains
[0963] The solid-phase phosphoramide synthesis method utilizes a blank CPG solid-phase support as the starting cycle, and nucleotide monomers are sequentially linked according to the antisense strand nucleotide arrangement. Each linkage of a nucleotide monomer involves four steps: deprotection, coupling, capping, and oxidation or thiolation. The synthesis conditions for 1 μmol of oligonucleotides in the antisense strand are the same as those for the sense strand.
[0964] 1.3 Purification and Annealing of Oligonucleotides
[0965] 1.3.1 Purification of Oligonucleotides
[0966] The synthesized solid-phase support (positive or negative chain) was added to 1.5 mL of liquid ammonia and reacted at 55 °C for 8 hours. The supernatant was lyophilized and the crude product was purified by RP-IP-HPLC to obtain the modified positive and negative chains shown in Tables 2 and 4.
[0967] 1.3.2 Annealing
[0968] According to Table 5, the sense strand (SS strand) and the antisense strand (AS strand) were mixed, heated to 95°C, and kept for 5 minutes until the reaction was complete. The mixture was then freeze-dried to obtain the corresponding siRNAs shown in Table 5.
[0969] 2. Preparation of siRNA with ligand linker
[0970] 1. Preparation of L96-containing justice chain
[0971] 1.1 The L96-CPG carrier was sourced from commercial procurement.
[0972] 1.2 Preparations before synthesis:
[0973] The standard phosphoramide monomer was dissolved in anhydrous acetonitrile. The phosphoramide monomer was a commercially available 2'-F, 2'-O-methyl and other modified phosphoramides. The concentration of the phosphoramide monomer in anhydrous acetonitrile was 0.08 M.
[0974] A 1 μmol synthesis column was prepared by loading L96-CPG solid support onto Empty SPE Cartridges (3 mL), and the specified sequence was synthesized using the phosphoramide coupling method.
[0975] 1.3 Solid-phase synthesis:
[0976] Oligonucleotide sequences were synthesized using phosphoramide technology in solid-phase synthesis. Synthesis was performed on a CPG-supported solid substrate using a Linkon 48-channel nucleic acid synthesizer, depending on the synthesis scale. The 5'-hydroxy dimethoxytriphenylmethyl (DMT) protecting group of the nucleotides was removed using a 3% dichloroacetic acid / toluene solution, followed by activating agent solution of 5-ethylthio-1H-tetrazole (ETT, 350 mM in acetonitrile). Phosphate ester bonds were constructed using an aqueous solution of iodine (50 mM); hydrogen yellow element (200 mM in pyridine solution) was used to introduce thiophosphate ester bonds. Unreacted active groups were capped using a mixture of acetic anhydride, N-methylimidazolium, pyridine, and acetonitrile (N-methylimidazolium / acetonitrile ratio 1:4; acetic anhydride / pyridine / acetonitrile ratio 2:3:5). The above steps were repeated until the sequence synthesis was complete.
[0977] 1.4 Ammonia Desorption Protection:
[0978] The cleavage and deprotection of the oligomers bound to the solid support were carried out after solid-phase synthesis. The dried solid support was treated with a concentrated ammonium hydroxide solution at 65°C for 2 hours. The solution was then evaporated and the solid residue was redissolved in water.
[0979] 1.5 Separation and purification:
[0980] Oligonucleotides were purified using preparative HPLC and a C18 column. Different fractions were collected by monitoring the UV absorbance at 260 nm to obtain the corresponding positive chains, which were then analyzed for purity on the HPLC instrument.
[0981] 2. Preparation of antisense chain
[0982] The preparation of the antisense chain was identical except that Universal CPG was used as the initial solid support.
[0983] 3-Double-chain annealing
[0984] The qualified sense and antisense chains were quantified separately using Nanodrop (calculated at 1OD = 33ug), and then mixed at a molar ratio of 1:1. The mixture was placed in a water bath at 70°C, heated for 10 minutes, and then removed and allowed to return to room temperature.
[0985] 4. Concentration and Drying
[0986] After annealing, the double-stranded samples were subjected to quality inspection. Once the quality inspection was passed, the double-stranded samples were dried in a vacuum centrifuge to obtain the corresponding siRNA.
[0987] Example 2: Inhibitory activity test in Huh7 cell line
[0988] 2.1 Materials
[0989] 2.1.1 Test Compound
[0990] Test compound: Prepared as a 100 μM stock solution using nuclease-free water.
[0991] 2.1.2 Cell lines
[0992] Huh7 cells were provided by WuXi AppTec. Huh7 cells were cultured in DMEM medium (Corning, catalog number 10-013-CV) containing 10% fetal bovine serum (FBS, ExCell Bio, catalog number FSP500), 1% penicillin-streptomycin (HyClone, catalog number SV30010), and 1% MEM NEAA (Gibco, catalog number 11140050).
[0993] 2.1.3 Main Instruments
[0994] The main instruments used in this experiment included a fluorescence qPCR instrument (Quanstudio 7flex), a thermal cycler (Bio-RAD T100), a centrifuge (Beckman Allegra-X15R Centrifuge), and a cell counter (Countstar Rigel S2).
[0995] 2.1.4 Main Reagents and Consumables
[0996] The main reagents used in this experiment included Lipofectamine. TM iRNAiMAX transfection reagent (INVITROGEN, catalog number 13778150), Opti-MEM (Gibco, catalog number 31985070), 2×AceQ Universal U+Probe Master Mix V2 (Vazyme, catalog number Q513-03-AA), EZ-Press 96RNA Purification Kit (EZB, catalog number EZ4001-L), III RT SuperMix for qPCR (+gDNA wiper) (Vazyme, catalog number R323-01), 96-well plate (Costar, catalog number 3599 or Sep, catalog number 803096), AO / PI (Countstar, catalog number RE010212). APOC3TaqMan TM Gene Expression Assay, GAPDH TaqMan TM Gene Expression Assay (Thermo, ID: Hs02786624_g1).
[0997] 2.2 Experimental Methods
[0998] 2.2.1 Compound transfection plate
[0999] The compound was introduced into Huh7 cells via transfection, as described below:
[1000] 1) Dilute siRNA with nuclease-free water to a final concentration of 12×;
[1001] 2) Dilution of Opti-MEM medium Reagent, incubate at room temperature for 15 minutes;
[1002] 3) Take 30 μL of diluted RNAiMax and mix it with an equal amount of diluted siRNA (v:v = 1:1) from step 1), and incubate at room temperature for 15 minutes to form a complex. At the same time, set up a control group without the compound transfection reagent.
[1003] 4) Inoculate with Huh7 cells (2×10⁻⁶) 4 Cells (per well) were transferred to 96-well cell plates. One or two concentration points were set for the test siRNA assay, with two replicates per well. A compound-free control group containing RNAi MAX was also included. Cells were incubated at 37°C for 24 hours in a 5% CO2 incubator.
[1004] 2.2.2 RNA extraction and reverse transcription
[1005] 24 hours after transfection, the culture medium was removed and cells were collected for RNA extraction. Total RNA was extracted using the EZ-Press 96 RNA Purification Kit (EZB-EZ4001-L) according to the kit instructions. III RT SuperMix for qPCR (+gDNA wiper) (Vazyme-R323-01) synthesizes cDNA.
[1006] 2.2.3 qPCR detection of target gene mRNA expression levels
[1007] The target cDNA will be detected by qPCR, and GAPDH cDNA will be detected simultaneously as an internal control for parallel testing.
[1008] Prepare the qPCR mixture as shown in Table 6 below.
[1009] Table 6 qPCR reaction system
[1010] Add 8 μL of the prepared PCR reaction solution and 2 μL of sample cDNA to each of the 384 wells.
[1011] The qPCR reaction program was as follows: heat at 95°C for 10 minutes, then enter the cycling mode, heat at 95°C for 15 seconds, then at 60°C for 1 minute, for a total of 40 cycles.
[1012] 2.2.4 Data Analysis
[1013] The expression level of the target gene mRNA in each sample was calculated using the ΔΔCt relative quantification method. The relative expression level of the target gene was calculated using a 2-1T / T ratio. -ΔΔCt express.
[1014] The calculation formula is as follows:
[1015] ΔCT = Average Ct value of target gene - Average Ct value of internal reference gene
[1016] ΔCt = ΔCT (drug-treated group) - ΔCT (RNAiMAX control group)
[1017] The relative expression level of the target gene APOC3 = 2 -ΔΔCT
[1018] APOC3 inhibition rate % = (1 - value of sample / Ave. value of RNAiMAX Control) * 100
[1019] Most of the siRNAs in Table 5 showed good inhibitory activity at concentrations of 10 nM and 1 nM. The results of the inhibition rate screening of some representative siRNAs at concentrations of 10 nM and 1 nM are shown in Table 7.
[1020] Table 7 Results of Huh7 cell line viability screening
[1021] "—" indicates that no detection was performed.
[1022] Example 3: IC50 value test in Huh7 cell line
[1023] 3.1 Materials
[1024] 3.1.1 Test Compound
[1025] Test compound: Prepared as a 100 μM stock solution using nuclease-free water.
[1026] 3.1.2 Cell lines
[1027] Huh7 cells were provided by WuXi AppTec. Huh7 cells were cultured in DMEM medium (Corning, catalog number 10-013-CV) containing 10% fetal bovine serum (FBS, ExCell Bio, catalog number FSP500), 1% penicillin-streptomycin (HyClone, catalog number SV30010), and 1% MEM NEAA (Gibco, catalog number 11140050).
[1028] 3.1.3 Main Instruments
[1029] The main instruments used in this experiment included a fluorescence qPCR instrument (Quanstudio 7flex), a thermal cycler (Bio-RAD T100), a centrifuge (Beckman Allegra-X15R Centrifuge), and a cell counter (Countstar Rigel S2).
[1030] 3.1.4 Main Reagents and Consumables
[1031] The main reagents used in this experiment included Lipofectamine. TM iRNAiMAX transfection reagent (INVITROGEN, catalog number 13778150), Opti-MEM (Gibco, catalog number 31985070), 2×AceQ Universal U+Probe Master Mix V2 (Vazyme, catalog number Q513-03-AA), EZ-Press 96RNA Purification Kit (EZB, catalog number EZ4001-L), III RT SuperMix for qPCR (+gDNA wiper) (Vazyme, catalog number R323-01), 96-well plate (Costar, catalog number 3599 or Sep, catalog number 803096), AO / PI (Countstar, catalog number RE010212). APOC3TaqMan TM Gene Expression Assay, GAPDH TaqMan TM Gene Expression Assay (Thermo, ID: Hs02786624_g1).
[1032] 3.2 Experimental Methods
[1033] 3.2.1 Compound transfection plate
[1034] The compound was introduced into Huh7 cells via transfection, as described below:
[1035] 1) Dilute siRNA with nuclease-free water to a final concentration of 12×;
[1036] 2) Dilution of Opti-MEM medium Reagent, incubate at room temperature for 15 minutes;
[1037] 3) Take 30 μL of diluted RNAiMax and mix it with an equal amount of diluted siRNA (v:v = 1:1) from step 1), and incubate at room temperature for 15 minutes to form a complex. At the same time, set up a control group without the compound transfection reagent.
[1038] 4) Inoculate with Huh7 cells (2×10⁻⁶) 4 Cells (per well) were transferred to 96-well cell plates. Six or seven concentration points were set for the test siRNA assay, with two replicates per well. A compound-free control group containing RNAi MAX was also included. Cells were incubated at 37°C for 24 hours in a 5% CO2 incubator.
[1039] 3.2.2 RNA extraction and reverse transcription
[1040] 24 hours after transfection, the culture medium was removed and cells were collected for RNA extraction. Total RNA was extracted using the EZ-Press 96 RNA Purification Kit (EZB-EZ4001-L) according to the kit instructions. III RT SuperMix for qPCR (+gDNA wiper) (Vazyme-R323-01) synthesizes cDNA.
[1041] 3.2.3 qPCR detection of target gene mRNA expression levels
[1042] The target cDNA will be detected by qPCR, and GAPDH cDNA will be detected simultaneously as an internal control for parallel testing.
[1043] Prepare the qPCR mixture as shown in Table 8 below.
[1044] Table 8 qPCR reaction system
[1045] Add 8 μL of the prepared PCR reaction solution and 2 μL of sample cDNA to each of the 384 wells.
[1046] The qPCR reaction program was as follows: heat at 95°C for 10 minutes, then enter the cycling mode, heat at 95°C for 15 seconds, then at 60°C for 1 minute, for a total of 40 cycles.
[1047] 3.2.4 Data Analysis
[1048] The expression level of the target gene mRNA in each sample was calculated using the ΔΔCt relative quantification method. The relative expression level of the target gene was calculated using a 2-1T / T ratio. -ΔΔCt express.
[1049] The calculation formula is as follows:
[1050] ΔCT = Average Ct value of target gene - Average Ct value of internal reference gene
[1051] ΔCt = ΔCT (drug-treated group) - ΔCT (RNAiMAX control group)
[1052] The relative expression level of the target gene APOC3 = 2 -ΔΔCT
[1053] APOC3 inhibition rate % = (1 - value of sample / Ave. value of RNAiMAX Control) * 100
[1054] The GraphPad Prism software was used for graphical analysis, and the inhibition rate results are expressed as mean ± SD.
[1055] The IC50 value was calculated by fitting a curve using GraphPad Prism software.
[1056] Most of the siRNAs in Table 5 have low IC50 values, and the experimental results of some representative siRNAs are shown in Table 9.
[1057] Table 9. IC50 test results in Huh7 cell line
[1058] Example 4: HepG2 cell line viability test
[1059] 4.1 Materials
[1060] 4.1.1 Test Compound
[1061] Test compound: Prepared as a 100 μM stock solution using nuclease-free water.
[1062] 4.1.2 Cell lines
[1063] HepG2 cells were provided by Kanglong Pharmaceutical (Beijing) New Drug Technology Co., Ltd. HepG2 cells were cultured in DMEM medium (Corning, catalog number 10-013-CV) containing 10% fetal bovine serum (FBS, Ausgenex catalog number FBS500-S), 1% penicillin-streptomycin (HyClone catalog number SV30010), and 1% MEM NEAA (Gibco catalog number 11140050).
[1064] 4.1.3 Main Instruments
[1065] The main instruments used in this experiment included a CO2 incubator (Thermo Scientific, catalog number 371), a microscope (Thermo, ID: Hs01586213_m1), and a fluorescence qPCR instrument (Applied Biosystems). Centrifuge (Eppendorf, 5810R), Countess III (Invitrogen, C10227).
[1066] 4.1.4 Main Reagents and Consumables
[1067] The main reagents and consumables used in this experiment included Lipofectaine. TM RNAiMAX transfection reagent (INVITROGEN, catalog number 13778150), Opti-MEM (Gibco, catalog number 31985070), Cells-to-cDNA kit (Vazyme, catalog number CL111), TaqMan™ Fast Advanced Master Mix (Invitrogen, catalog number 4444965), Primer and probe for GAPDH(VIC) (thermofisher, Hs99999903_m1), Primer and probe for APOC3(FAM) (thermofisher, Hs00163644_m1), 96-well plate (Corning, catalog number 3904) EnduraPlateTM Optical 384-well Blue Reaction Plate with Barcode (Applied Biosystems, Cat. No. 4483320), TrypLE (Gibco, 12604021).
[1068] 4.2 Experimental Methods
[1069] 4.2.1 Compound transfection plate
[1070] The compound was introduced into HepG2 cells via transfection, as described below:
[1071] 1) Dilute siRNA with nuclease-free water to a final concentration of 12×;
[1072] 2) Dilution of Opti-MEM medium Reagent, incubate at room temperature for 15 minutes;
[1073] 3) Take 30 μL of diluted RNAiMax and mix it with an equal amount of diluted siRNA (v:v = 1:1) from step 1), and incubate at room temperature for 15 minutes to form a complex. At the same time, set up a control group without the compound transfection reagent.
[1074] 4) Seed HepG2 cells (8000 cells / well) into 96-well cell plates. Set 1 or 2 concentration points for the siRNA inhibition rate assay and 6 or 7 concentration points for the IC50 assay. Perform two replicates. Include a control group containing RNAiMAX without the compound. Incubate at 37°C in a 5% CO2 incubator for 24 hours.
[1075] 4.2.2 RNA extraction and reverse transcription
[1076] 24 hours after transfection, the culture medium was removed and the cells were collected for RNA extraction. cDNA was synthesized using the Cells-to-cDNA kit according to the kit instructions.
[1077] 4.2.3 qPCR detection of target gene mRNA expression levels
[1078] The target cDNA will be detected by qPCR, and GAPDH cDNA will be detected simultaneously as an internal control for parallel testing.
[1079] Prepare the qPCR mixture as shown in Table 10 below.
[1080] Table 10 qPCR reaction system
[1081] The qPCR reaction program was as follows: heat at 50°C for 2 minutes, heat at 95°C for 20 seconds, then enter the cycling mode, heat at 95°C for 1 second, then heat at 60°C for 20 seconds, for a total of 40 cycles.
[1082] 4.2.4 Data Analysis
[1083] The expression level of the target gene mRNA in each sample was calculated using the ΔΔCt relative quantification method. The relative expression level of the target gene was calculated using a 2-1T / T ratio. -ΔΔCt express.
[1084] The calculation formula is as follows:
[1085] ΔCT = Average Ct value of target gene - Average Ct value of internal reference gene
[1086] ΔCt = ΔCT (drug-treated group) - ΔCT (RNAiMAX control group)
[1087] The relative expression level of the target gene APOC3 = 2 -ΔΔCT
[1088] APOC3 inhibition rate % = (1 - value of sample / Ave. value of RNAiMAX Control) * 100, and the inhibition rate results are expressed as mean ± SD.
[1089] Statistical analysis was performed using GraphPad Prism software, curves were fitted, and IC50 values were calculated.
[1090] Most of the siRNAs in Table 5 showed good inhibitory activity and low IC50 values at concentrations of 10 nM and 1 nM. The results of the inhibition rate screening and IC50 value test of some representative siRNAs at concentrations of 10 nM and 1 nM are shown in Tables 11 and 12.
[1091] Table 11 Results of HepG2 cell line viability screening
[1092] Table 12 Results of IC50 test for HepG2 cell line
[1093] Example 5: Primary monkey hepatocyte (PCH) activity assay
[1094] 5.1 Materials
[1095] 5.1.1 Test Compound
[1096] Test compound: Prepared as a 100 μM stock solution using nuclease-free water.
[1097] 5.1.2 Cell lines
[1098] Primary monkey hepatocytes (PCH) were provided by WuXi AppTec.
[1099] 5.1.3 Main Instruments
[1100] The main instruments used in this experiment included a fluorescence qPCR instrument (Quanstudio 7flex), a thermal cycler (Bio-RAD T100), a centrifuge (Beckman Allegra-X15R Centrifuge), and a cell counter (Countstar Rigel S2).
[1101] 5.1.4 Main Reagents and Consumables
[1102] The main reagents used in this experiment included hepatocyte resuscitation medium (Miaoshun Biotechnology), hepatocyte maintenance medium (Miaoshun Biotechnology), fetal bovine serum (ExcellBio), penicillin-specific antibodies (Hyclone), nuclease-free water (Thermo), 2×AceQ Universal U+Probe Master Mix V2 (Vazyme, catalog number Q513-03-AA), and EZ-Press 96RNA Purification Kit (EZB, catalog number EZ4001-L). III RT SuperMix for qPCR (+gDNA wiper) (Vazyme, catalog number R323-01), 96-well plate (Costar, catalog number 3599 or Sep, catalog number 803096), AO / PI (Countstar, catalog number RE010212). APOC3 TaqMan TM Gene Expression Assay, GAPDH TaqMan TM Gene Expression Assay (Thermo, ID: Hs02786624_g1).
[1103] 5.2 Experimental Methods
[1104] 5.2.1 Compound Plating
[1105] The compound enters PCH cells via free uptake, as described below:
[1106] PCH cells were added to resuscitation medium, centrifuged at 50g for 2 minutes, and then resuspended in maintenance medium. After cell counting, the cell suspension was seeded into 96-well collagen-coated cell plates (4.5 × 10⁻⁶). 4 Cells / well), while plating, the test siRNA was added to the cell plate. The test siRNA was tested starting at a concentration of 100 nM, diluted 10-fold, and 6 or 7 concentration points were set up; a control group containing only cells and no compound was also set up. Incubate at 37°C in a 5% CO2 incubator for 48 hours.
[1107] 5.2.2 RNA extraction and reverse transcription
[1108] After 48 hours of cell culture, the culture medium was removed and the cells were collected for RNA extraction. Total RNA was extracted using the EZ-Press 96 RNA Purification Kit (EZB-EZ4001-L) according to the kit instructions. III RT SuperMix for qPCR (+gDNA wiper) (Vazyme-R323-01) synthesizes cDNA.
[1109] 5.2.3 qPCR detection of target gene mRNA expression levels
[1110] The target cDNA will be detected by qPCR, and GAPDH cDNA will be detected simultaneously as an internal control for parallel testing.
[1111] Prepare the qPCR mixture as shown in Table 13 below.
[1112] Table 13 qPCR reaction system
[1113] Add 8 μL of the prepared PCR reaction solution and 2 μL of sample cDNA to each of the 384 wells.
[1114] The qPCR reaction program was as follows: heat at 95°C for 10 minutes, then enter the cycling mode, heat at 95°C for 15 seconds, then at 60°C for 1 minute, for a total of 40 cycles.
[1115] 5.2.4 Data Analysis
[1116] The expression level of the target gene mRNA in each sample was calculated using the ΔΔCt relative quantification method. The relative expression level of the target gene was calculated using a 2-1T / T ratio. -ΔΔCt express.
[1117] The calculation formula is as follows:
[1118] ΔCT = Average Ct value of target gene - Average Ct value of internal reference gene
[1119] ΔCt = ΔCT (drug-treated group) - ΔCT (compound-free control group)
[1120] The relative expression level of the target gene APOC3 = 2 -ΔΔCT
[1121] APOC3 inhibition rate%=(1-value of sample / Ave.value of RNase free water Control)*100
[1122] The GraphPad Prism software was used for graphical analysis, and the inhibition rate results are expressed as mean ± SD.
[1123] The IC50 value was calculated by fitting a curve using GraphPad Prism software.
[1124] The IC50 test results of some representative siRNAs are shown in Table 14.
[1125] Table 14. IC50 assay results of representative siRNA-derived primary monkey hepatocytes (PCH)
[1126] Example 6: Activity and RNA-seq Off-target Assessment and Validation in Primary Human Hepatocytes (PHH)
[1127] 6.1 Materials
[1128] 6.1.1 Test Compound
[1129] Test compound: Prepared as a 100 μM stock solution using nuclease-free water.
[1130] 6.1.2 Cell lines
[1131] Primary human hepatocytes (PHH) were provided by WuXi AppTec New Drug Development Co., Ltd.
[1132] 6.1.3 Main Instruments
[1133] The main instruments used in this experiment included a fluorescence qPCR instrument (Quanstudio 7 flex), a thermal cycler (Bio-RAD T100), a centrifuge (Beckman Allegra-X15R Centrifuge), and a cell counter (Countstar Rigel S2).
[1134] 6.1.4 Main Reagents and Consumables
[1135] The main reagents used in this experiment included hepatocyte resuscitation medium (Miaoshun Biotechnology), hepatocyte maintenance medium (Miaoshun Biotechnology), fetal bovine serum (ExcellBio), penicillin-specific antibodies (Hyclone), nuclease-free water (Thermo), 2×AceQ Universal U+Probe Master Mix V2 (Vazyme, catalog number Q513-03-AA), and EZ-Press 96RNA Purification Kit (EZB, catalog number EZ4001-L). III RT SuperMix for qPCR (+gDNA wiper) (Vazyme, catalog number R323-01), 2×Color SYBR Green qPCR Master Mix (ROX2) (EZB-A0012-R2-L), RNA Extraction Kit (RNeasy Mini Kit), Agilent RNA Analysis Kit (Agilent DNF-471RNA Kit (15nt)), Transcriptome Library Construction Kit ( Universal V10 RNA-seq Library Prep Kit (Premixed Version), Double-stranded Deoxyribonucleic Acid High-Sensitivity Concentration Assay Kit (Qubit 1X dsDNA HS Assay Kit), Deoxyribonucleic Acid Card Frame (Standard Cartridge), Next-Generation Sequencing High-Throughput Kit (NovaSeq 6000S4 Reagent Kit v1.5 (300 cycles), 96-well plate (Costar, catalog number 3599 or Saipu, catalog number 803096), AO / PI (Countstar, catalog number RE010212). APOC3 TaqMan TM Gene Expression Assay, GAPDH TaqMan TM Gene Expression Assay (Thermo, ID: Hs02786624_g1). Primer sequences for potential off-target genes used are shown in Table 15 below:
[1136] Table 15 Primer sequences of potential off-target genes
[1137] 6.2 Experimental Methods
[1138] 6.2.1 Compound Plating
[1139] The compound enters PHH cells via free uptake, as described below:
[1140] PHH cells were added to resuscitation medium, centrifuged at 50g for 2 minutes, and then resuspended in maintenance medium. After cell counting, the cell suspension was seeded into 96-well collagen-coated cell plates (5.4 × 10⁻⁶). 4 Cells / well), while plating, the test siRNA was added to the cell plate. The test siRNA was tested starting at a concentration of 100 nM, diluted 10-fold, and 6 or 7 concentration points were set up; a control group containing only cells and no compound was also set up. Incubate at 37°C in a 5% CO2 incubator for 48 hours.
[1141] 6.2.2 RNA extraction and RNA-seq
[1142] After culturing cells for 48 hours, the culture medium was removed and the cells were collected according to the manufacturer's instructions (Qiagen-74106_). Total RNA was purified from cells using the Mini Kit guidelines. Total RNA concentration was detected using NanoDrop One, and RNA integrity was analyzed using the Agilent RNA Analyzer according to the kit instructions. Library construction and quality control were then performed, followed by sequencing according to the manufacturer's (Illumina-NovaSeq 6000\Illumina-20028314_NovaSeq 6000S4 Reagent Kit v1.5(300cycles)) guidelines.
[1143] Standard analysis of RNAseq data includes: (1) quality control of Fastq sequence files; (2) removal of adapters and low-quality sequences from Fastq files; (3) alignment of sequences to the genome; (4) counting of sequences covering each gene region; (5) normalized counting matrix; (6) PCA clustering and heatmap analysis; (7) differentially expressed gene analysis; (8) GO and KEGG pathway enrichment analysis.
[1144] Potential off-target genes identified will be further validated using qPCR detection.
[1145] 6.2.3 RNA extraction and reverse transcription
[1146] After 48 hours of cell culture, the culture medium was removed and the cells were collected for RNA extraction. Total RNA was extracted using the EZ-Press 96 RNA Purification Kit (EZB-EZ4001-L) according to the kit instructions. III RT SuperMix for qPCR (+gDNA wiper) (Vazyme-R323-01) synthesizes cDNA.
[1147] 6.2.4 qPCR detection of mRNA expression levels of target genes and potential off-target genes
[1148] Target cDNA and potential off-target cDNA will be detected by qPCR, while GAPDH cDNA will be detected as an internal control for parallel testing.
[1149] Prepare the qPCR mixture to detect the target gene, as shown in Table 16 below.
[1150] Table 16 qPCR reaction system
[1151] Prepare a qPCR mixture to detect potential off-target genes, as shown in Table 17 below.
[1152] Table 17 qPCR reaction system
[1153] Add 8 μL of the prepared PCR reaction solution and 2 μL of sample cDNA to each of the 384 wells.
[1154] The Taq-man qPCR reaction program is as follows: heat at 95°C for 10 minutes, then enter the cycling mode, heat at 95°C for 15 seconds, then at 60°C for 1 minute, for a total of 40 cycles.
[1155] The SYBR qPCR reaction program is as follows: heat at 95℃ for 5 minutes, then enter the cycling mode, heat at 95℃ for 5 seconds, then at 60℃ for 30 seconds, for a total of 40 cycles, and finally heat at 95℃ for 15 seconds, at 60℃ for 1 minute, and at 95℃ for 15 seconds.
[1156] 6.2.5 Data Analysis
[1157] The expression level of the target gene (or potential off-target target gene) mRNA in each sample was calculated using the ΔΔCt relative quantification method. The relative expression level of the target gene was calculated using a 2-1T / T ratio. -ΔΔCt express.
[1158] The calculation formula is as follows:
[1159] ΔCT = Average Ct value of target gene - Average Ct value of internal reference gene
[1160] ΔCt = ΔCT (drug-treated group) - ΔCT (compound-free control group)
[1161] relative expression level of target gene = 2 -ΔΔCT
[1162] The inhibition rate of the target gene is calculated as (1 - value of sample / Ave. value of RNase free water control) * 100. The inhibition rate is expressed as mean ± SD.
[1163] Statistical analysis was performed using GraphPad Prism software, curves were fitted, and IC50 values were calculated.
[1164] 6.2.6 Gene Off-Target Risk Assessment
[1165] The off-target risk was verified and assessed by calculating the ratio of the IC50 of potential off-target genes to the IC50 of target genes. Specific risk assessment criteria are shown in Table 18.
[1166] Table 18 Risk Assessment Criteria
[1167] Most of the siRNAs in Table 5 showed low off-target risk. The off-target risk test results of some representative siRNAs are shown in Table 19.
[1168] Table 19. Results of representative siRNA off-target risk testing
[1169] Example 7: In vivo activity testing method
[1170] The pharmacodynamics of the corresponding siRNAs in Table 5 were evaluated in the B6-hAPOC3-Tg mouse model.
[1171] 7.1 Model Construction and Grouping
[1172] B6-hAPOC3-Tg mice, 6-8 weeks old, male, provided by Jicui Yaokang, were defined as D(-2) two days before administration. Whole blood was collected after fasting for 4-5 hours. Grouping was based on body weight and plasma APOC3 and triglyceride (TG) levels as the main indicators. The day of grouping was defined as D(-1).
[1173] 7.2 Dosage and Test Sample Preparation Information
[1174] The siRNA in Table 5 was prepared using enzyme-free PBS (manufacturer / supplier: MK, catalog number: MS3553) as a concentrated stock solution, and then diluted to 0.6 mg / ml. A single dose was administered on day 0 via subcutaneous injection into the abdomen at a dose of 1 or 3 MPa, with a volume of 5 μL / g × mouse body weight (g).
[1175] 7.3 Data Acquisition
[1176] Mouse body weight was measured weekly after drug administration. Whole blood was collected from mice on days 7 (D7), 14 (D14), 21 (D21), 28 (D28), 42 (D42), and 56 (D56) after drug administration, and plasma was separated. The levels of APOC3 protein, total cholesterol (TC), triglycerides (TG), and low-density lipoprotein-C (LDL-C) in the plasma were measured using an ELISA kit (Apolipoprotein C3 Human ELISA Kit, Invitrogen, EHAPOC3).
[1177] After reaching the experimental endpoint, livers were harvested from all mice, and the expression level of APOC3 mRNA in the liver was detected by quantitative real-time PCR.
[1178] Most of the siRNAs listed in Table 5 exhibited good APOC3 protein inhibitory activity in mouse models, showing good inhibitory activity as early as 14 days after administration and maintaining high inhibitory activity even after 56 days. The in vivo activity data of some representative siRNAs in mice are shown in Table 20 below:
[1179] Table 20. Inhibitory activity of representative siRNAs against APOC3 protein in mouse serum.
[1180] a. The corresponding dosage is in parentheses.
[1181] b. "—" indicates that no detection was performed.
[1182] The experimental results of Example 7 show that most of the siRNAs in Table 5 can reduce APOC3 protein levels, total cholesterol (TC) levels, triglyceride (TG) levels, and low-density lipoprotein-C (LDL-C) levels in the in vivo model. In particular, even at low doses (e.g., 1 mpk), they can still significantly reduce serum APOC3 protein levels, total cholesterol (TC) levels, triglyceride (TG) levels, and low-density lipoprotein-C (LDL-C) levels for a relatively long period of time (6 weeks or more after administration).
[1183] Example 8: In vivo activity test in cynomolgus monkeys
[1184] The pharmacodynamics of the corresponding siRNAs in Table 5 were evaluated in healthy cynomolgus monkeys.
[1185] 8.1 Experimental Animals and Grouping
[1186] Crab-eating macaques, male, weighing approximately 5-6 kg, were provided by Pengli Biotechnology. The 7 days prior to drug administration were defined as D(-7). Whole blood was collected from the limb veins. Grouping was based on body weight and serum APOC3 and triglyceride (TG) levels as the main indicators. The day of drug administration was defined as D0.
[1187] 8.2 Dosage and Test Sample Preparation Information & Main Reagents
[1188] In Table 5, the siRNA was prepared using physiological saline to create a concentrated stock solution, which was then diluted to 3 mg / ml. A single administration was given on day 0 via subcutaneous injection into the shoulder and back, at a dose of 3 MPa and a volume of 1 ml / kg × the weight of the cynomolgus monkey (kg).
[1189] The main reagents used included the RNeasy Plus Mini Kit (Qiagen, 74134), EZscript All-in-one Reverse Transcription Kit (with DNase) (Yingze, RT3), Multiplex Probe qPCR Master Mix (ROX2) (Yingze, EZ3304-R22), Apoc3 probe (Applied Biosystems, Mf02794312_m1), and Gapdh probe (Applied Biosystems, Mf04392546_g1).
[1190] 8.3 Data Acquisition
[1191] Weight was measured every 2 weeks after drug administration. Whole blood was collected and serum separated on days 7 (D7), 14 (D14), 21 (D21), 28 (D28), 42 (D42), and 56 (D56) after drug administration. The levels of APOC3 protein, total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) in plasma were measured using an ELISA kit. Approximately 10 mg of liver tissue was collected via ultrasound-guided puncture on days -7, 28, and 56, and the expression level of APOC3 mRNA in the liver was detected using quantitative real-time PCR.
[1192] After RNA was extracted from liver tissue, cDNA was synthesized using the EZscript All-in-one Reverse Transcription Kit (with DNase) (RT3) according to the kit instructions. The target cDNA will be detected by qPCR, and GAPDH cDNA will be detected simultaneously as an internal control for parallel testing.
[1193] Prepare the qPCR mixture as shown in Table 21 below.
[1194] Table 21 qPCR reaction system
[1195] The qPCR reaction program was as follows: heat at 95°C for 10 minutes, then enter the cycling mode, heat at 95°C for 15 seconds, followed by heating at 60°C for 1 minute, for a total of 40 cycles.
[1196] 8.4 Data Analysis
[1197] The expression level of the target gene mRNA in each sample was calculated using the ΔΔCt relative quantification method. The relative expression level of the target gene was calculated using a 2-1T / T ratio. -ΔΔCt express.
[1198] The calculation formula is as follows:
[1199] ΔCT = Average Ct value of target gene - Average Ct value of internal reference gene
[1200] ΔCt = ΔCT (drug-treated group) - ΔCT (control group)
[1201] The relative expression level of the target gene APOC3 = 2 -ΔΔCT
[1202] APOC3 inhibition rate % = (1 - value of sample / Ave. value of control) * 100
[1203] The GraphPad Prism software was used for graphical analysis, and the inhibition rate results are expressed as mean ± SD.
[1204] Table 22 below shows some representative siRNA activity data:
[1205] Table 22 Inhibitory activity of representative siRNAs in cynomolgus monkey blood against APOC3 protein
[1206] The experimental results in Example 8 showed that most of the siRNAs listed in Table 5 significantly reduced serum APOC3 protein levels and liver APOC3 mRNA levels in healthy cynomolgus monkeys. In particular, even after prolonged administration (4 weeks or more), they still significantly reduced serum APOC3 protein levels and liver APOC3 mRNA levels.
[1207] In summary, the in vitro and in vivo activity evaluation results show that the siRNA of the present invention can significantly inhibit APOC3 gene expression after a long period of administration, while the off-target activity evaluation results show that the siRNA of the present invention has low off-target activity.
Claims
A double-stranded nucleotide (dsRNA) for inhibiting the expression of apolipoprotein C3 (APOC3) in cells, characterized in that, The dsRNA comprises a sense strand and an antisense strand forming a double-stranded region, wherein the length of the sense strand and the antisense strand are each independently 15-30 nucleotides, and the antisense strand comprises at least 15 consecutive nucleotide sequences that differ from SEQ ID NO:1 by 1, 2, 3, 4 or 5 nucleotides. The dsRNA as described in claim 1, characterized in that, The antisense strand has one or more nucleotide differences at positions 1, 2, 17, 18 and 19 in the 5'-3' direction selected from SEQ ID NO:
1. The dsRNA as described in claim 1, characterized in that, The antisense strand has one or two nucleotide differences in the first, second, 17, 18 and 19 of SEQ ID NO:1 in the 5'-3' direction. The dsRNA as described in claim 1, characterized in that, the antisense strand comprises at least 15 consecutive nucleotides of the sequence as set forth in N1N2ACUGAGAAUACUGUN 17 N 18 N 19 GUN 22 N 23 the antisense strand comprises at least 15 consecutive nucleotides of the sequence as set forth in N1N2ACUGAGAAUACUGUN N 22 is absent, A, or U; N 23 is absent, A, or U; N1 is either U or A; N2 can be C, U, or A; N 17 is C or U; N 18 is C, G or A; and, N 19 is C, G, or U. The dsRNA as described in claim 4 is characterized in that, The dsRNA satisfies any of the following conditions: N1 is A, N2 is C, N 17 is C, N 18 is A and N 19 is C; N1 is A, N2 is C, N 17 is C, N 18 is C and N 19 is U; N1is U, N2is C, N 17 is U, N 18 is C and N 19 is C; N1is U, N2is C, N 17 is C, N 18 is C and N 19 is U; N1 is A, N2 is C, N 17 is C, N 18 is G and N 19 is C; N1is U, N2is U or A, N 17 is C, N 18 is C and N 19 is G; N1 is A, N2 is C, N 17 is U, N 18 is C and N 19 is C; N1is U, N2is A or U, N 17 is U, N 18 is C and N 19 is C; N1 is A, N2 is A, N 17 is U, N 18 is C and N 19 is C; N1is U, N2is A or U, N 17 is C, N 18 is A and N 19 is C; N1 is A, N2 is A or U, N 17 is C, N 18 is A and N 19 is C; N1is U, N2is A or U, N 17 is C, N 18 is C and N 19 is U; N1 is A, N2 is A, N 17 is C, N 18 is C and N 19 is U; N 22 for A and N 23 for U; N 22 U and N 23 A; N 22 for A and N 23 for A; N 22 N 23 N N1 is A, N2 is C, N 17 is C, N 18 is A, N 19 is C, N 22 is A and N 23 is U; N1 is A, N2 is C, N 17 is C, N 18 is A, N 19 is C, N 22 is A and N 23 is A; N1 is A, N2 is C, N 17 is C, N 18 is A, N 19 is C, N 22 is U and N 23 is A; N1 is A, N2 is C, N 17 is C, N 18 is A, N 19 is C, N 22 is U and N 23 is U; N1 is A, N2 is C, N 17 N1 is A, N2 is C, N 18 N1 is A, N2 is C, N 19 N1 is A, N2 is C, N 22 N1 is A, N2 is C, N 23 N1 is A, N2 is C, N N1 is A, N2 is C, N 17 is C, N 18 is C, N 19 is U, N 22 is A and N 23 is A; N1 is A, N2 is C, N 17 is C, N 18 is C, N 19 is U, N 22 is U and N 23 is A; and, N1 is A, N2 is C, N 17 N1 is A, N2 is C, N 18 N1 is A, N2 is C, N 19 N1 is A, N2 is C, N 22 N1 is A, N2 is C, N 23 N1 is A, N2 is C, N The dsRNA as described in claim 1, characterized in that, The positive strand comprises at least 15 consecutive nucleotide sequences that differ from SEQ ID NO:3 by 1, 2, 3, 4 or 5 nucleotides. The dsRNA as described in claim 1, characterized in that, The positive strand has one or more nucleotide differences at positions 3, 4, 5, 20 and 21 selected from SEQ ID NO:3 in the 5'-3' direction. The dsRNA as described in claim 1, characterized in that, The positive strand has one or two nucleotide differences in the 3rd, 4th, 5th, 20th and 21st nucleotides selected from SEQ ID NO:3 in the 5'-3' direction. The dsRNA as described in claim 1, characterized in that, the sense strand comprises at least 15 contiguous nucleotides of the sequence of AGUAUUCUCAGUUCUUGUUGU 20 N’ 21 the sense strand comprises at least 15 contiguous nucleotides of the sequence of AGUAUUCUCAGUUCUUGUUGU N' 21 is U or A; N' 20 is G, U or A; N'5 is either G or A; N'4 is C, G, or U; and, N'3 can be C, G, or A. The dsRNA as described in claim 9 is characterized in that, The dsRNA satisfies any of the following conditions: N' 21 is G, N' 20 is G, N'5 is G, N'4 is U and N'3 is G; N' 21 is G, N' 20 is G, N'5 is G, N'4 is G and N'3 is A; N' 21 N' 20 N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' N' 21 A, N' 20 G, N'5G, N'4G and N'3A; N' 21 G, N' 20 G, N'5G, N'4C and N'3G; N' 21 A, N' 20 U or A, N'5 is G, N'4 is G and N'3 is C; N' 21 is G, N' 20 is G, N'5 is A, N'4 is G and N'3 is G; N' 21 For A and N' 20 For A or U, N'5 is A, N'4 is G and N'3 is G; N' 21 U, N' 20 U, N'5 is A, N'4 is G and N'3 is G; N' 21 N' 20 N'5 is A or U, N'4 is G, and N'3 is G; N' 21 is U, N' 20 is A or U, N'5 is G, N'4 is U and N'3 is G; N' 21 N' 20 N'5 is G, N'4 is G and N'3 is A; and, N' 21 U, N' 20 U, N'5 is G, N'4 is G and N'3 is A. The dsRNA according to any one of claims 1-10 is characterized in that, The dsRNA is siRNA. The dsRNA as described in claim 1, characterized in that, The length of the double-stranded region is 15-25 nucleotide pairs, preferably 16-23 nucleotide pairs, and more preferably 19-21 nucleotide pairs. The dsRNA as described in claim 1, characterized in that, The antisense strand has a length of 19, 20, 21, 22, or 23 nucleotides. The dsRNA as described in claim 1, characterized in that, The length of the justice chain is 19, 20, or 21 nucleotides. The dsRNA as described in claim 1, characterized in that, The antisense strand is 21, 22, or 23 nucleotides long, and the sense strand is 19, 20, or 21 nucleotides long. The dsRNA as described in claim 1, characterized in that, The antisense strand is 23 nucleotides long, and the sense strand is 21 nucleotides long. The dsRNA as described in claim 1, characterized in that, One or both of the sense strand and the antisense strand contain a 3' overhang and / or a 5' overhang of at least one nucleotide, for example, one or both of the sense strand and the antisense strand contain a 3' overhang and / or a 5' overhang of at least two nucleotides. The dsRNA as described in claim 17 is characterized in that, The protruding end is selected from U, UU, UUU, AA, AG, GG and UA. The dsRNA as described in claim 17 is characterized in that, The protruding end is selected from U, UU, UUU and AA. The dsRNA as described in claim 1, characterized in that, The antisense strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences as shown in any of SEQ ID NO: 61, 67, 73, 75, 78, and 86-98. The dsRNA as described in claim 1, characterized in that, The antisense chain comprises any of the sequences shown in SEQ ID NO:61, 67, 73, 75, 78 and 86-98. The dsRNA as described in claim 1, characterized in that, The antisense strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences, as shown in SEQ ID NO:90 or SEQ ID NO:
95. The dsRNA as described in claim 1, characterized in that, The antisense strand contains a nucleotide sequence as shown in SEQ ID NO:90 or SEQ ID NO:
95. The dsRNA as described in claim 1, characterized in that, The positive chain comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, or at least 21 consecutive nucleotide sequences as shown in any of SEQ ID NO: 14, 20, 26, 28, 31, and 39-51. The dsRNA as described in claim 1, characterized in that, The justice chain comprises any of the sequences shown in SEQ ID NO:14, 20, 26, 28, 31 and 39-51. The dsRNA as described in claim 1, characterized in that, The positive chain comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, or at least 21 consecutive nucleotide sequences as shown in SEQ ID NO:43 or SEQ ID NO:
48. The dsRNA as described in claim 1, characterized in that, The positive strand contains a nucleotide sequence as shown in SEQ ID NO:43 or SEQ ID NO:
48. The dsRNA as described in claim 1, characterized in that, The dsRNA contains any of the following pairs of paired sense and antisense sequences: (1): Justice chain: SEQ ID NO:14, Antisense chain: SEQ ID NO:61; (2): Justice chain: SEQ ID NO:20, Antisense chain: SEQ ID NO:67; (3): Justice chain: SEQ ID NO:26, Antisense chain: SEQ ID NO:73; (4): Justice chain: SEQ ID NO:28, Antisense chain: SEQ ID NO:75; (5): Justice chain: SEQ ID NO:31, Antisense chain: SEQ ID NO:78; (6): Justice chain: SEQ ID NO:39, Antisense chain: SEQ ID NO:86; (7): Justice chain: SEQ ID NO:40, Antisense chain: SEQ ID NO:87; (8): Justice chain: SEQ ID NO:41, Antisense chain: SEQ ID NO:88; (9): Justice chain: SEQ ID NO:42, Antisense chain: SEQ ID NO:89; (10): Justice chain: SEQ ID NO:43, Antisense chain: SEQ ID NO:90; (11): Justice chain: SEQ ID NO:44, Antisense chain: SEQ ID NO:91; (12): Justice chain: SEQ ID NO:45, Antisense chain: SEQ ID NO:92; (13): Justice chain: SEQ ID NO:46, Antisense chain: SEQ ID NO:93; (14): Justice chain: SEQ ID NO:47, Antisense chain: SEQ ID NO:94; (15): Justice chain: SEQ ID NO:48, Antisense chain: SEQ ID NO:95; (16): Justice chain: SEQ ID NO:49, Antisense chain: SEQ ID NO:96; (17): Justice chain: SEQ ID NO:50, Antisense chain: SEQ ID NO:97; and, (18): Justice chain: SEQ ID NO:51, Antisense chain: SEQ ID NO:
98. The dsRNA according to any one of claims 1-28 is characterized in that, substantially all nucleotides of the positive strand and substantially all nucleotides of the negative strand are modified nucleotides; preferably, all nucleotides of the positive strand and all nucleotides of the negative strand are modified nucleotides. The dsRNA as described in claim 29 is characterized in that, The sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of: 2'-O-methyl modification, 2'-fluoro modification, 2'-O-methoxyethyl (MOE) modification, 2'-deoxynucleotide, unlocked nucleic acid nucleotide (UNA), glycol nuclec acid nucleotide (GNA), (E)-vinylphosphonate nucleotide, reverse nucleotide, reverse abase-free nucleotide, and modifications involving inter-nucleotide bonding of thiophosphate nucleotides. The dsRNA as described in claim 29 is characterized in that, The sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of: 2'-O-methyl modification, 2'-fluoro modification, 2'-O-methoxyethyl (MOE) modification, 2'-deoxynucleotide, unlocked nucleic acid nucleotide (UNA), glycolnuclec acid nucleotide (GNA), reverse nucleotide, reverse abase-free nucleotide, and modifications involving inter-nucleotide bonding of phosphate thioester nucleotides. The dsRNA as described in claim 29 is characterized in that, The antisense chain satisfies any of the following conditions: The antisense strand has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 6, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 6, 8, 9, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 4, 6, 8, 10, 14, 16, and 18; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 4, 6, 12, 14, 16, 18, 20; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 1, 2, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 9, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 12, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 14, 16, and 20; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 9, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 1, 2, 10, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 9, 10, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 1, 2, 9, 10, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 12, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 1, 2, 12, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 6, 7, 8, 9, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 10, 12, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 3, 10, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 4, 10, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 6, 10, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counting from the 5' end) at positions 2, 8, 10, 14, and 16; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 14, 16, and 18; The antisense strand has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 14, 16, and 20; The antisense strand has 1, 2, or 3 2'-deoxynucleotides (DNA); The antisense strand has one 2'-deoxynucleotide (DNA) and is located at position 12, 14 or 15 (counting from the 5' end); preferably, the antisense strand has one 2'-deoxynucleotide (DNA) and is located at position 15 (counting from the 5' end); The antisense strand has one, two, or three nucleotides modified with 2'-O-methoxyethyl (MOE); The antisense strand has one 2'-O-methoxyethyl (MOE) modified nucleotide and is located at position 9 or 10 (counting from the 5' end); The antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 9 and 10 (counting from the 5' end); The antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 3 and 15 (counting from the 5' end); The antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 3 and 20 (counting from the 5' end); The antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 3 and 21 (counting from the 5' end); The antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides located at positions 5 and 15 (counting from the 5' end); The antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides, located at positions 5 and 20 (counting from the 5' end); The antisense strand has two 2'-O-methoxyethyl (MOE) modified nucleotides, located at positions 5 and 21 (counting from the 5' end); The antisense strand has 1-4 phosphate thioester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23; The antisense strand has phosphate ester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23; The antisense strand has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1, and (counting from the 5' end) two 2'-O-methoxyethyl (MOE) nucleotides at positions 5 and 15; The antisense strand has a 2'-fluorinated nucleotide at position 1 (counting from the 5' end) and a 2'-deoxynucleotide (DNA) at position 15 (counting from the 5' end); The antisense strand has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1, (counting from the 5' end) two 2'-O-methoxyethyl (MOE) nucleotides at positions 5 and 15, and (counting from the 5' end) one 2'-deoxynucleotide (DNA) at position 15. The antisense strand has five 2'-fluoro modified nucleotides (counting from the 5' end) at positions 1, 2, 10, 14, and 16, and two 2'-O-methoxyethyl (MOE) modified nucleotides (counting from the 5' end) at positions 5 and 15. The antisense strand has five 2'-fluoro modified nucleotides (counting from the 5' end) at positions 2, 10, 12, 14, and 16, and two 2'-O-methoxyethyl (MOE) modified nucleotides (counting from the 5' end) at positions 5 and 15. The antisense strand has five 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 10, 14, and 16, and one 2'-deoxynucleotide (DNA) at position 15 (counting from the 5' end); and The antisense strand has five 2'-fluorinated nucleotides (counting from the 5' end) at positions 1, 2, 10, 14, and 16, two 2'-O-methoxyethyl (MOE) nucleotides (counting from the 5' end) at positions 5 and 15, and one 2'-deoxynucleotide (DNA) at position 15 (counting from the 5' end). The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 6, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 6, 8, 9, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 7, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 4, 6, 8, 10, 14, 16, and 18, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 5, 7, 9, 11, 12, 13, 15, 17, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 4, 6, 12, 14, 16, 18, and 20, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 5, 7, 8, 9, 10, 11, 13, 15, 17, 19, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 9, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 12, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 14, 16, and 20, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 9, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 9, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 9, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 1, 2, 12, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 12, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at position 9; and nucleotides with 2'-O-methyl modification at positions 3, 4, 5, 6, 7, 8, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 12, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at position 10; and nucleotides with 2'-O-methyl modification at positions 3, 4, 5, 6, 7, 8, 9, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 12, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 9 and 10; and nucleotides with 2'-O-methyl modification at positions 3, 4, 5, 6, 7, 8, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 3 and 15; and nucleotides with 2'-O-methyl modification at positions 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 1, 2, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 3, 4, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 14, and 16; 2'-deoxynucleotides (DNA) at position 12; and 2'-O-methylated nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 12, and 16; 2'-deoxynucleotides (DNA) at position 14; and 2'-O-methylated nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 12, 14, and 16; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methylated nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 1, 2, 10, 14, and 16; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methylated nucleotides at positions 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) 2'-fluoro-modified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl-modified nucleotides at positions 3 and 20; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl-modified nucleotides at positions 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) 2'-fluoro-modified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl-modified nucleotides at positions 3 and 21; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl-modified nucleotides at positions 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) 2'-fluoromodified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl modified nucleotides at positions 5 and 20; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl modified nucleotides at positions 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) 2'-fluoromodified nucleotides at positions 1, 2, 10, 14, and 16; 2'-O-methoxyethyl modified nucleotides at positions 5 and 21; 2'-deoxynucleotides (DNA) at position 15; and 2'-O-methyl modified nucleotides at positions 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 10, 12, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 13, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 12, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluoro modification at positions 2, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 3, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 4, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 3, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 4, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 4, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 5, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 6, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 7, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 6, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 8, 10, 14, and 16; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 8, 10, 14, and 16, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 10, 14, 16, and 18; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 17, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 14, 16, and 18, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 19, 20, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 2, 10, 14, 16, and 20; nucleotides with 2'-O-methoxyethyl (MOE) modification at positions 5 and 15; and nucleotides with 2'-O-methyl modification at positions 1, 3, 4, 6, 7, 8, 9, 11, 12, 13, 17, 18, 19, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 2, 10, 14, 16, and 20, and nucleotides with 2'-O-methyl modifications at positions 1, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 17, 18, 19, 21, 22, and 23; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2, nucleotide positions 2 and 3, nucleotide positions 21 and 22, and nucleotide positions 22 and 23. The dsRNA as described in claim 29 is characterized in that, The positive chain has a length of 19, 20, or 21 nucleotides. The dsRNA as described in claim 78 is characterized in that, The justice chain satisfies any of the following conditions: The positive strand has (counting from the 5' end) nucleotides with 2'-fluorinated modification at positions 13 and 15; The positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11 and 13; The positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11 and 15; The positive strand has (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13 and 15; The positive strand has (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 9, 11, 13 and 15; The positive strand has 1, 2 or 3 2'-deoxynucleotides (DNA); The positive strand has 1, 2 or 3 2'-deoxynucleotides (DNA), and one of them is located at position 20 (counting from the 5' end); The positive strand has 1, 2 or 3 2'-deoxynucleotides (DNA), and one of them is located at position 1, 2, 3 or 4 (counting from the 5' end); The positive strand has one 2'-deoxynucleotide (DNA), and one of them is located at position 3 or 4 (counting from the 5' end); The positive strand has one 2'-deoxynucleotide (DNA), and one of them is located at position 3 (counting from the 5' end); The positive strand has one 2'-deoxynucleotide (DNA), and one of them is located at position 4 (counting from the 5' end); The positive strand has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end), and one 2'-deoxynucleotide (DNA) at position 3 or 4 (counting from the 5' end). The positive strand has one 2'-deoxynucleotide (DNA) and is located at position 7, 10, or 20 (counting from the 5' end); The positive strand has two 2'-deoxynucleotides (DNA), one of which is located at position 1, 2, 3 or 4 (counting from the 5' end), and the other is located at position 20 (counting from the 5' end). The positive strand has 1, 2, or 3 unlocked nucleic acid nucleotides (UNA). The positive strand has 1-4 phosphate thioester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21; and, The positive strand has phosphate ester nucleotide bonds located (counting from the 5' end) between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3. The dsRNA as described in claim 78 is characterized in that, The positive strand has a length of 21 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 9, 10, 11, and 13, and nucleotides with 2'-O-methyl modifications at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 15, 16, 17, 18, 19, 20, and 21; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3. The dsRNA as described in claim 78 is characterized in that, The positive strand has a length of 21 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 9, 10, 11, and 15, and nucleotides with 2'-O-methyl modifications at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 13, 14, 16, 17, 18, 19, 20, and 21; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3. The dsRNA as described in claim 78 is characterized in that, The positive strand has a length of 21 nucleotides and has (i) (counting from the 5' end) nucleotides with 2'-fluorinated modifications at positions 9, 10, 11, 13, and 15, and nucleotides with 2'-O-methyl modifications at positions 1, 2, 3, 4, 5, 6, 7, 8, 12, 14, 16, 17, 18, 19, 20, and 21; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3. The dsRNA as described in claim 78 is characterized in that, The positive strand has a length of 21 nucleotides and has (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13, and 15; 2'-deoxynucleotides (DNA) at position 4; and 2'-O-methyl nucleotides at positions 1, 2, 3, 5, 6, 7, 8, 12, 14, 16, 17, 18, 19, 20, and 21; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3. The dsRNA as described in claim 78 is characterized in that, The positive strand has a length of 21 nucleotides and has (i) (counting from the 5' end) 2'-fluorinated nucleotides at positions 9, 10, 11, 13, and 15; 2'-deoxynucleotides (DNA) at position 3; and 2'-O-methyl nucleotides at positions 1, 2, 4, 5, 6, 7, 8, 12, 14, 16, 17, 18, 19, 20, and 21; and / or (ii) (Counting from the 5' end) Phosphophosphate nucleotide bonds located between nucleotide positions 1 and 2 and between nucleotide positions 2 and 3. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1 and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) 2'-fluorinated nucleotides at positions 13 and 15. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at positions 13 and 15, and a 2'-deoxynucleotide (DNA) at position 3. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at position 1, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has (counting from the 5' end) a 2'-fluorinated nucleotide at positions 13 and 15, and a 2'-deoxynucleotide (DNA) at position 4. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end) and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end). The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end), and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end), and 2'-deoxynucleotide (DNA) at position 3. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and contains 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end), and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and contains 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end), and 2'-deoxynucleotide (DNA) at position 4. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 2, 10, 12, 14 and 16 (counting from the 5' end), and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end), and 2'-deoxynucleotide (DNA) at position 4. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 2, 10, 12, 14 and 16 (counting from the 5' end), and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end), and 2'-deoxynucleotide (DNA) at position 3. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 2, 10, 12, 14 and 16 (counting from the 5' end) and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 13 and 15 (counting from the 5' end). The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end) and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 9, 10, 11, 13 and 15 (counting from the 5' end). The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end) and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 9, 10, 11, 13 and 15 (counting from the 5' end) and 2'-deoxynucleotide (DNA) at position 3. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 1, 2, 10, 14 and 16 (counting from the 5' end) and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 9, 10, 11, 13 and 15 (counting from the 5' end) and 2'-deoxynucleotide (DNA) at position 4. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 12, 14 and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 9, 10, 11, 13 and 15, and 2'-deoxynucleotide (DNA) at position 4. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 2, 10, 12, 14 and 16, and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides (counted from the 5' end) at positions 9, 10, 11, 13 and 15, and 2'-deoxynucleotide (DNA) at position 3. The dsRNA as described in claim 29 is characterized in that, The antisense strand has a length of 23 nucleotides and has 2'-fluorinated nucleotides at positions 2, 10, 12, 14 and 16 (counting from the 5' end) and 2'-O-methoxyethyl nucleotides at positions 5 and 15; the sense strand has a length of 21 nucleotides and has 2'-fluorinated nucleotides at positions 9, 10, 11, 13 and 15 (counting from the 5' end). The dsRNA according to any one of claims 29-99 is characterized in that, The first nucleotide at the 5' end of the antisense strand is selected from the following structures: Where Base is a base A, U, G, C, T or other nucleotide bases, and R is H, methoxy, F or methoxyethoxy. The dsRNA as described in claim 100 is characterized in that, The 5' end of the antisense strand contains (E)-vinylphosphonate nucleotide. The dsRNA according to any one of claims 29-101 is characterized in that, The antisense chain comprises an antisense chain sequence selected from any of the items shown in Table 4. The dsRNA according to any one of claims 29-101 is characterized in that, The antisense chain comprises an antisense chain sequence selected from any one of SEQ ID NO:665, 776-806, 851, 963-993. The dsRNA according to any one of claims 29-101 is characterized in that, The justice chain comprises a sequence of justice chains selected from any of the items shown in Table 2. The dsRNA according to any one of claims 29-101 is characterized in that, The justice chain comprises a justice chain sequence selected from any one of SEQ ID NO:203, 314-344. The dsRNA according to any one of claims 29-101 is characterized in that, The dsRNA comprises a pair of sense and antisense sequences selected from any of the pairs in Tables 5-1, 5-2, and 5-3. The dsRNA according to any one of claims 29-101 is characterized in that, The dsRNA contains a pair of sense and antisense sequences selected from any of the pairs in Table 5-1. The dsRNA according to any one of claims 1-107 is characterized in that, The dsRNA is further conjugated to a ligand moiety containing N-acetylgalactosamine, preferably with the 3' end of the positive strand conjugated to the ligand moiety. The dsRNA as described in claim 108 is characterized in that, The ligand has the following structure: This indicates the position where the dsRNA is attached to the positive strand via a phosphate group or a thiophosphate group. The dsRNA as described in claim 108 is characterized in that, The ligands are selected from the group consisting of formulas II to XXXI: Where Y is 0 or S and n is an integer from 3 to 6 (Equation XXIV); Where Y is 0 or S and n is an integer from 3 to 6 (equation XXV); Where X is O or S (Equation XXVII); This indicates the position where the dsRNA is attached to the positive strand via a phosphate group or a thiophosphate group. The dsRNA as described in claim 108 is characterized in that, The ligand is selected from the following structures: This indicates the linking bond between the ligand and dsRNA or siRNA. The dsRNA as described in claim 108 is characterized in that, The dsRNA is coupled to the ligand as shown below: Where X is O or S, preferably X is O. The dsRNA as described in claim 108 is characterized in that, The justice chain comprises a sequence of justice chains selected from any of the items shown in Table 3. The dsRNA as described in claim 108 is characterized in that, The justice chain comprises a justice chain sequence selected from any one of SEQ ID NO:389, 500-530. The dsRNA as described in claim 108 is characterized in that, The dsRNA contains a pair of sense and antisense sequences selected from any of the pairs in Table 5-2. A modified double-stranded nucleotide (dsRNA), characterized in that, The dsRNA comprises a sense strand and an antisense strand forming a double-stranded region, wherein the nucleotide sequence of the sense strand is as follows: 5'-X1X2X3X4X5X6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 As shown in -3', where X1-X 21 Each of the bases is independently A, U, G, C, T or other nucleotide bases; and: (1) X 13 and / or X 15 is a 2'-fluoro modified nucleotide; and / or, (2) one or more of X3, X4, and X 20 are 2’-deoxynucleotides (DNA). The dsRNA as described in claim 116 is characterized in that, The dsRNA is siRNA. The dsRNA as described in claim 116 is characterized in that, substantially all nucleotides of the sense strand and substantially all nucleotides of the antisense strand are modified nucleotides; preferably, all nucleotides of the sense strand and all nucleotides of the antisense strand are modified nucleotides. The dsRNA as described in claim 116 is characterized in that, The justice chain satisfies any of the following conditions: X 13 and X 15 is a 2’-fluoro modified nucleotide, and X3, X4or X 20 is a 2’-deoxy nucleotide (DNA); X 13 and X 15 is a 2'-fluoro modified nucleotide, and X3or X4is a 2'-deoxynucleotide (DNA); X9, X 10 and X 11 one or more of X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27 X9, X 10 , X 11 , X 13 and X 15 are 2’-fluoro modified nucleotides; X9, X 10 , X 11 , X 13 and X 15 is a 2’-fluoro modified nucleotide, and X3is a 2’-deoxynucleotide (DNA); X9, X 10 , X 11 , X 13 and X 15 is a 2’-fluoro modified nucleotide, and X4is a 2’-deoxynucleotide (DNA); and, X9, X 10 , X 11 , X 13 and X 15 is a 2’-fluoro modified nucleotide, and X 20 is a 2’-deoxynucleotide (DNA). The dsRNA as described in claim 119 is characterized in that, The nucleotides at other positions are 2'-O-methyl modified nucleotides; and / or, X1 and X2 and / or X2 and X3 are linked by 3',5'-phosphothioester bonds. The dsRNA as described in claim 116 is characterized in that, The justice chain satisfies any of the following conditions: X9, X 10 , X 11 , X 13 and X 15 are 2’-fluoro modified nucleotides, and X1-X8, X 12 , X 14 and X 16 - X 21 are 2’-O-methyl modified nucleotides; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X2 is a 2'-deoxynucleotide (DNA), X3 is X4-X8, X4-X2, X3-X4-X5, X6-X7-X8, X7-X8-X9 ... 12 X 14 and X 16 -X 21 It is a nucleotide modified with 2'-O-methyl, and X1 and X2 are linked by 3',5'-phosphothiodiester bonds and X2 and X3 are linked by 3',5'-phosphothiodiester bonds; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; X9, X 10 X 11 X 13 and X 15 X1-X3, X5-X8, X4 are 2'-fluorinated nucleotides, X4 is 2'-deoxynucleotide (DNA), X1-X3, X5-X8, X4 are 2'-fluorinated nucleotides, X5-X8 are 2'-fluorinated nucleotides, X4 is 2'-deoxynucleotide (DNA), X5-X3, X5-X8, X4 are 2'-fluorinated nucleotides, X5-X3 are 2'- 12 X 14 and X 16 -X 21 It is a nucleotide modified with 2'-O-methyl, and X1 and X2 are linked by 3',5'-phosphothiodiester bonds and X2 and X3 are linked by 3',5'-phosphothiodiester bonds; X9, X 10 X 11 X 13 and X 15 X is a nucleotide with a 2'-fluorine modification. 20 It is a 2'-deoxynucleotide (DNA) and X1-X8, X 12 X 14 and X 16 -X 19 and X 21 Nucleotides modified with 2'-O-methyl; and, X9, X 10 X 11 X 13 and X 15 X is a nucleotide with a 2'-fluorine modification. 20 It is a 2'-deoxynucleotide (DNA), X1-X8, X 12 X 14 and X 16 -X 19 and X 21 It is a nucleotide modified with 2'-O-methyl, and X1 and X2 are linked by 3',5'-phosphothioester bonds and X2 and X3 are linked by 3',5'-phosphothioester bonds. The dsRNA as described in claim 116 is characterized in that, The nucleotide sequence of the antisense strand is as follows: 5'-Y1Y2Y3Y4Y5Y6Y7Y8Y9Y 10 Y 11 Y 12 Y 13 Y 14 Y 15 Y 16 Y 17 Y 18 Y 19 Y 20 Y 21 Y 22 Y 23 As shown in -3', where Y1-Y 21 Each of the bases is independently A, U, G, C, T, or other nucleotide bases; Y 22 and / or Y 23 It exists or does not exist; if it exists, Y 22 and Y 23 Each of the bases is independently A, U, G, C, T or other nucleotide bases. The dsRNA as described in claim 122 is characterized in that, Y1, Y2, Y3, Y4, Y6, Y8, Y 10 Y 12 Y 14 Y 15 Y 16 Y 18 and Y 20 One or more of the nucleotides are 2'-fluorinated, such as 3, 4 or 5. The dsRNA as described in claim 123 is characterized in that, The antisense chain satisfies any of the following conditions: Y1, Y2, Y 10 , Y 14 and Y 16 are 2’-fluoro modified nucleotides; Y2, Y 10 , Y 12 , Y 14 and Y 16 are 2’-fluoro modified nucleotides; Y2, Y 14 and Y 16 is a 2’-fluoro modified nucleotide; Y2, Y3, Y 10 , Y 14 and Y 16 are 2’-fluoro modified nucleotides; Y2, Y4, Y 10 , Y 14 and Y 16 are 2’-fluoro modified nucleotides; Y2, Y6, Y 10 , Y 14 and Y 16 are 2’-fluoro modified nucleotides; Y2, Y8, Y 10 , Y 14 and Y 16 are 2’-fluoro modified nucleotides; Y2, Y 10 , Y 14 , Y 16 and Y 18 are 2’-fluoro modified nucleotides; Y2, Y 10 , Y 14 , Y 16 and Y 20 are 2’-fluoro modified nucleotides; Y2, Y5, Y 10 , Y 14 and Y 16 are 2’-fluoro modified nucleotides; and, Y2, Y 10 , Y 14 , Y 15 and Y 16 are 2’-fluoro modified nucleotides. The dsRNA according to any one of claims 122-124 is characterized in that, Y5 and / or Y 15 is a 2'-0-methoxyethyl modified nucleotide; Preferably, Y5 and Y 15 A nucleotide modified with 2'-O-methoxyethyl; or, Y 15 It is a 2'-deoxynucleotide (DNA). The dsRNA according to any one of claims 122-125 is characterized in that, The nucleotides at other positions are nucleotides modified with a 2'-O-methyl group; and / or, the first nucleotide at the 5' end of the antisense strand is selected from the following structures: Where Base is a base A, U, G, C, T or other nucleotide bases, and R is H, methoxy, F or methoxyethoxy. The dsRNA as described in claim 126 is characterized in that, The 5' end of the antisense strand contains (E)-vinylphosphonate nucleotide. The dsRNA according to any one of claims 122-127 is characterized in that, one or more of Y1and Y2, Y2and Y3, Y 21 and Y 22 between and Y 22 and Y 23 are linked by 3', 5'-phosphorothioate diester bonds. The dsRNA as described in claim 122 is characterized in that, The antisense chain satisfies any of the following conditions: Y1, Y2, Y 10 Y 14 and Y 16 These are nucleotides with 2'-fluorination modification, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are gaps between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds; Y1, Y2, Y 10 Y 14 and Y 16 These are nucleotides with 2'-fluorination modification, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide; Y1, Y2, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds; Y1, Y2, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 Y 13 Y 15 and Y 17 -Y 23 A nucleotide modified with 2'-O-methyl and between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl and between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide; Y2, Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y5, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y 10 Y 14 Y 15 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y4-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y3, Y5-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y5, Y7-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y7-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y8, Y 10 , Y 14 and Y 16 are 2’-fluoro modified nucleotides, Y1, Y3-Y7, Y9, Y 11 -Y 13 , Y 15 and Y 17 -Y 23 are 2’-O-methyl modified nucleotides; optionally, the 5’ terminus of the antisense strand comprises an (E)-vinyl phosphonate nucleotide; Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y7, Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 Y 17 -Y 19 and Y 21 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 17 -Y 19 and Y 21 -Y 23 A nucleotide modified with a 2'-O-methyl group; optionally, the 5' end of the antisense strand comprises an (E)-vinylphosphonate nucleotide; and, Y1, Y2, Y 10 Y 14 and Y 16 Y is a nucleotide with 2'-fluorination modification. 15 It is a 2'-deoxynucleotide (DNA), Y3-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-phosphothioester bonds; optionally, the 5' end of the antisense chain contains an (E)-vinylphosphonate nucleotide. The dsRNA according to any one of claims 122-129 is characterized in that, The modification satisfies any of the following conditions: X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X2 is a 2'-deoxynucleotide (DNA), and X3 is a 2'-deoxynucleotide (DNA). X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 These are nucleotides modified with a 2'-O-methyl group, and X1 and X2 are linked by 3',5'-phosphothioester bonds; Y1, Y2, Y... 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are differences between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are gaps between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 These are nucleotides with 2'-fluorination modification, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are gaps between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 These are nucleotides with 2'-fluorination modification, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 It is a 2'-fluorinated nucleotide, and X1-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are gaps between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y1, Y2, Y 10 Y 14 and Y 16 These are nucleotides with 2'-fluorination modification, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are gaps between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y7-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y7, Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 17 -Y 19 and Y 21 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y4-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y3, Y5-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y5, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y5, Y7-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y7, Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 Y 17 -Y 19 and Y 21 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 Y 13 Y 15 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 12 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 Y 13 and Y 17 -Y 23 Nucleotides modified with 2'-O-methyl, between Y1 and Y2, between Y2 and Y3, Y 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-thiophosphate diester bonds, and the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X4 is a 2'-deoxynucleotide (DNA), and X1-X3, X5-X8, X 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 15 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y4, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3, Y6-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y7-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y7, Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides that are 2'-fluorinated, Y5 and Y 15 Nucleotides modified with 2'-O-methoxyethyl, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 17 -Y 19 and Y 21 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y3, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y4-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y4, Y 10 Y 14 and Y 16 Nucleotides that are 2'-fluorinated, Y1, Y3, Y5-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y5, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y4, Y6-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y6, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y5, Y7-Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 Nucleotides modified with 2'-O-methyl; Y2, Y8, Y 10 Y 14 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y7, Y9, Y 11 -Y 13 Y 15 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 18 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 and Y 17 Y 19 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 16 and Y 20 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 Y 15 Y 17 -Y 19 and Y 21 -Y 23 It is a nucleotide modified with 2'-O-methyl; optionally, the 5' end of the antisense strand contains an (E)-vinylphosphonate nucleotide; X9, X 10 X 11 X 13 and X 15 X1 is a 2'-fluorinated modified nucleotide, X3 is a 2'-deoxynucleotide (DNA), and X1-X2, X4-X8, X... 12 X 14 and X 16 -X 21 A nucleotide modified with a 2'-O-methyl group; Y2, Y 10 Y 14 Y 15 and Y 16 Nucleotides with 2'-fluorination modification, Y1, Y3-Y9, Y 11 -Y 13 and Y 17 -Y 23 A nucleotide modified with a 2'-O-methyl group; optionally, the 5' end of the antisense strand comprises an (E)-vinylphosphonate nucleotide; and, X9, X 10 X 11 X 13 and X 15 X is a nucleotide with a 2'-fluorine modification. 20 It is a 2'-deoxynucleotide (DNA), X1-X8, X 12 X 14 and X 16 -X 19 and X 21 These are nucleotides modified with a 2'-O-methyl group, and X1 and X2 are linked by 3',5'-phosphothiodiester bonds; Y1, Y2, Y... 10 Y 14 and Y 16 Y is a nucleotide with a 2'-fluorine modification. 15 It is a 2'-deoxynucleotide (DNA), Y3-Y9, Y 11 -Y 13 and Y 17 -Y 23 It is a nucleotide modified with 2'-O-methyl, and there are gaps between Y1 and Y2, between Y2 and Y3, and between Y... 21 and Y 22 Between and Y 22 and Y 23 They are linked by 3',5'-phosphothioester bonds; optionally, the 5' end of the antisense chain contains (E)-vinylphosphonate nucleotides. The dsRNA according to any one of claims 122-130 is characterized in that, The dsRNA is further conjugated to a ligand moiety containing N-acetylgalactosamine, preferably with the 3' end of the positive strand conjugated to the ligand moiety. The dsRNA as described in claim 131 is characterized in that, The ligand has the following structure: This indicates the position where the dsRNA is attached to the positive strand via a phosphate group or a thiophosphate group. The dsRNA as described in claim 131 is characterized in that, The ligands are selected from the group consisting of formulas II to XXXI: Where Y is 0 or S and n is an integer from 3 to 6 (Equation XXIV); Where Y is 0 or S and n is an integer from 3 to 6 (equation XXV); Where X is O or S (Equation XXVII); This indicates the position where the dsRNA is attached to the positive strand via a phosphate group or a thiophosphate group. The dsRNA as described in claim 131 is characterized in that, The ligand is selected from the following structures: This indicates the linking bond between the ligand and dsRNA or siRNA. The dsRNA as described in claim 131 is characterized in that, The dsRNA is coupled to the ligand as shown below: Where X is O or S, preferably X is O. The dsRNA according to any one of claims 116-135 is characterized in that, The dsRNA is used to inhibit the expression of apolipoprotein C3 (APOC3) in cells. The dsRNA as described in claim 136 is characterized in that, The antisense strand comprises at least 15 consecutive nucleotide sequences that differ from SEQ ID NO:1 by 1, 2, 3, 4 or 5 nucleotides. The dsRNA as described in claim 137 is characterized in that, The antisense strand has one or more nucleotide differences at positions 1, 2, 17, 18 and 19 in the 5'-3' direction selected from SEQ ID NO:
1. The dsRNA as described in claim 137 is characterized in that, The antisense strand has one or two nucleotide differences in the first, second, 17, 18 and 19 of SEQ ID NO:1 in the 5'-3' direction. The dsRNA as described in claim 137 is characterized in that, The antisense chain includes, for example, N1N2ACUGA GAAUACUGUN 17 N 18 N 19 GUN 22 N 23 The sequence shown consists of at least 15 consecutive nucleotide sequences; wherein: N 22 For non-existent, A or U; N 23 For non-existent, A or U; N1 is either U or A; N2 can be C, U, or A; N 17 For C or U; N 18 It is C, G, or A; and, N 19 It can be C, G, or U. The dsRNA as described in claim 140 is characterized in that, The dsRNA satisfies any of the following conditions: N1 is A, N2 is C, N 17 For C, N 18 For A and N 19 The answer is C; N1 is A, N2 is C, N 17 For C, N 18 For C and N 19 For U; N1 is U, N2 is C, N 17 For U, N 18 For C and N 19 The answer is C; N1 is U, N2 is C, N 17 For C, N 18 For C and N 19 For U; N1 is A, N2 is C, N 17 For C, N 18 For G and N 19 The answer is C; N1 is U, N2 is U or A, N 17 For C, N 18 For C and N 19 G; N1 is A, N2 is C, N 17 For U, N 18 For C and N 19 The answer is C; N1 is U, N2 is A or U, N 17 For U, N 18 For C and N 19 The answer is C; N1 is A, N2 is A, N 17 For U, N 18 For C and N 19 The answer is C; N1 is U, N2 is A or U, N 17 For C, N 18 For A and N 19 The answer is C; N1 is A, N2 is A or U, N 17 For C, N 18 For A and N 19 The answer is C; N1 is U, N2 is A or U, N 17 For C, N 18 For C and N 19 For U; N1 is A, N2 is A, N 17 For C, N 18 For C and N 19 For U; N 22 For A and N 23 For U; N 22 For U and N 23 A; N 22 For A and N 23 A; N 22 For U and N 23 For U; N1 is A, N2 is C, N 17 For C, N 18 For A and N 19 For C, N 22 For A and N 23 For U; N1 is A, N2 is C, N 17 For C, N 18 For A and N 19 For C, N 22 For A and N 23 A; N1 is A, N2 is C, N 17 For C, N 18 For A and N 19 For C, N 22 For U and N 23 A; N1 is A, N2 is C, N 17 For C, N 18 For A and N 19 For C, N 22 For U and N 23 For U; N1 is A, N2 is C, N 17 For C, N 18 For C, N 19 For U, N 22 For A and N 23 For U; N1 is A, N2 is C, N 17 For C, N 18 For C, N 19 For U, N 22 For A and N 23 A; N1 is A, N2 is C, N 17 For C, N 18 For C, N 19 For U, N 22 For U and N 23 For A; and, N1 is A, N2 is C, N 17 For C, N 18 For C, N 19 For U, N 22 For U and N 23 For U. The dsRNA as described in claim 137 is characterized in that, The positive strand comprises at least 15 consecutive nucleotide sequences that differ from SEQ ID NO:3 by 1, 2, 3, 4 or 5 nucleotides. The dsRNA as described in claim 137 is characterized in that, The positive strand has one or more nucleotide differences at positions 3, 4, 5, 20 and 21 selected from SEQ ID NO:3 in the 5'-3' direction. The dsRNA as described in claim 137 is characterized in that, The positive strand has one or two nucleotide differences in the 3rd, 4th, 5th, 20th and 21st nucleotides selected from SEQ ID NO:3 in the 5'-3' direction. The dsRNA as described in claim 137 is characterized in that, The justice chain includes, for example, ACN'3N'4N'5ACAGUAUUCUCAGUN'. 20 N' 21 The sequence shown consists of at least 15 consecutive nucleotide sequences; wherein: N' 21 It can be U or A; N' 20 For G, U, or A; N'5 is either G or A; N'4 is C, G, or U; and, N'3 can be C, G, or A. The dsRNA as described in claim 145 is characterized in that, The dsRNA satisfies any of the following conditions: N' 21 For U, N' 20 G, N'5 is G, N'4 is U and N'3 is G; N' 21 For U, N' 20 G is G, N'5 is G, N'4 is G and N'3 is A; N' 21 For A and N' 20 G is G, N'5 is A, N'4 is G and N'3 is G; N' 21 For A and N' 20 G is G, N'5 is G, N'4 is G and N'3 is A; N' 21 For U, N' 20 G, N'5 is G, N'4 is C and N'3 is G; N' 21 For A and N' 20 For U or A, N'5 is G, N'4 is G and N'3 is C; N' 21 For U, N' 20 G is G, N'5 is A, N'4 is G and N'3 is G; N' 21 For A and N' 20 For A or U, N'5 is A, N'4 is G and N'3 is G; N' 21 For U, N' 20 U, N'5, A, N'4, G, and N'3, G; N' 21 For A and N' 20 For A or U, N'5 is G, N'4 is U and N'3 is G; N' 21 For U, N' 20 For A or U, N'5 is G, N'4 is U and N'3 is G; N' 21 For A and N' 20 For A or U, N'5 is G, N'4 is G and N'3 is A; and, N' 21 For U, N' 20 Let U be N'5, G be N'4, G be N'3, and A be N'3. The dsRNA as described in claim 137 is characterized in that, One or both of the sense strand and the antisense strand contain a 3' overhang and / or a 5' overhang of at least one nucleotide, for example, one or both of the sense strand and the antisense strand contain a 3' overhang and / or a 5' overhang of at least two nucleotides. The dsRNA as described in claim 147 is characterized in that, The protruding end is selected from U, UU, UUU, AA, AG, GG and UA. The dsRNA as described in claim 147 is characterized in that, The protruding end is selected from U, UU, UUU and AA. The dsRNA as described in claim 137 is characterized in that, The antisense strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences as shown in any of SEQ ID NO: 61, 67, 73, 75, 78, and 86-98. The dsRNA as described in claim 137 is characterized in that, The antisense chain comprises any of the sequences shown in SEQ ID NO:61, 67, 73, 75, 78 and 86-98. The dsRNA as described in claim 137 is characterized in that, The antisense strand comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, at least 21 consecutive nucleotide sequences, at least 22 consecutive nucleotide sequences, or at least 23 consecutive nucleotide sequences, as shown in SEQ ID NO:90 or SEQ ID NO:
95. The dsRNA as described in claim 137 is characterized in that, The antisense strand contains a nucleotide sequence as shown in SEQ ID NO:90 or SEQ ID NO:
95. The dsRNA as described in claim 137 is characterized in that, The positive chain comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, or at least 21 consecutive nucleotide sequences as shown in any of SEQ ID NO: 14, 20, 26, 28, 31, and 39-51. The dsRNA as described in claim 137 is characterized in that, The justice chain comprises any of the sequences shown in SEQ ID NO:14, 20, 26, 28, 31 and 39-51. The dsRNA as described in claim 137 is characterized in that, The positive chain comprises at least 15 consecutive nucleotide sequences, at least 16 consecutive nucleotide sequences, at least 17 consecutive nucleotide sequences, at least 18 consecutive nucleotide sequences, at least 19 consecutive nucleotide sequences, at least 20 consecutive nucleotide sequences, or at least 21 consecutive nucleotide sequences as shown in SEQ ID NO:43 or SEQ ID NO:
48. The dsRNA as described in claim 137 is characterized in that, The positive strand contains a nucleotide sequence as shown in SEQ ID NO:43 or SEQ ID NO:
48. The dsRNA as described in claim 137 is characterized in that, The dsRNA contains any of the following pairs of paired sense and antisense sequences: (1): Justice chain: SEQ ID NO:14, Antisense chain: SEQ ID NO:61; (2): Justice chain: SEQ ID NO:20, Antisense chain: SEQ ID NO:67; (3): Justice chain: SEQ ID NO:26, Antisense chain: SEQ ID NO:73; (4): Justice chain: SEQ ID NO:28, Antisense chain: SEQ ID NO:75; (5): Justice chain: SEQ ID NO:31, Antisense chain: SEQ ID NO:78; (6): Justice chain: SEQ ID NO:39, Antisense chain: SEQ ID NO:86; (7): Justice chain: SEQ ID NO:40, Antisense chain: SEQ ID NO:87; (8): Justice chain: SEQ ID NO:41, Antisense chain: SEQ ID NO:88; (9): Justice chain: SEQ ID NO:42, Antisense chain: SEQ ID NO:89; (10): Justice chain: SEQ ID NO:43, Antisense chain: SEQ ID NO:90; (11): Justice chain: SEQ ID NO:44, Antisense chain: SEQ ID NO:91; (12): Justice chain: SEQ ID NO:45, Antisense chain: SEQ ID NO:92; (13): Justice chain: SEQ ID NO:46, Antisense chain: SEQ ID NO:93; (14): Justice chain: SEQ ID NO:47, Antisense chain: SEQ ID NO:94; (15): Justice chain: SEQ ID NO:48, Antisense chain: SEQ ID NO:95; (16): Justice chain: SEQ ID NO:49, Antisense chain: SEQ ID NO:96; (17): Justice chain: SEQ ID NO:50, Antisense chain: SEQ ID NO:97; and, (18): Justice chain: SEQ ID NO:51, Antisense chain: SEQ ID NO:
98. The dsRNA as described in claim 137 is characterized in that, The antisense chain comprises an antisense chain sequence selected from any of the items shown in Table 4. The dsRNA as described in claim 137 is characterized in that, The antisense chain comprises an antisense chain sequence selected from any one of SEQ ID NO:665, 776-806, 851 and 963-993. The dsRNA as described in claim 137 is characterized in that, The justice chain comprises a sequence of justice chains selected from any of the items shown in Table 2. The dsRNA as described in claim 137 is characterized in that, The justice chain comprises a justice chain sequence selected from any one of SEQ ID NO:203 and 314-344. The dsRNA as described in claim 137 is characterized in that, The justice chain comprises a sequence of justice chains selected from any of the items shown in Table 3. The dsRNA as described in claim 137 is characterized in that, The justice chain comprises a justice chain sequence selected from any one of SEQ ID NO:389 and 500-530. The dsRNA as described in claim 137 is characterized in that, The dsRNA comprises a pair of sense and antisense sequences selected from any of the pairs in Tables 5-1, 5-2, and 5-3. The dsRNA as described in claim 137 is characterized in that, The dsRNA contains a pair of sense and antisense sequences selected from any of the pairs in Table 5-1. The dsRNA as described in claim 137 is characterized in that, The dsRNA contains a pair of sense and antisense sequences selected from any of the pairs in Table 5-2. A vector comprising a nucleotide sequence encoding a dsRNA as described in any one of claims 1-187. A cell containing the dsRNA or vector as described in any one of claims 1-187. A pharmaceutical composition comprising dsRNA as described in any one of claims 1-187, a vector as described in claim 168, or a cell as described in claim 169, and optionally a pharmaceutically acceptable carrier or excipient. A kit comprising dsRNA as described in any one of claims 1-187, a vector as described in claim 168, or a cell as described in claim 169. A method for reducing apolipoprotein C3 (APOC3) in a subject, the method comprising administering to the subject an effective amount of dsRNA as described in any one of claims 1-187, a vector as described in claim 168, a cell as described in claim 169, or a pharmaceutical composition as described in claim 170. The use of the dsRNA as described in any one of claims 1-187, the vector as described in claim 168, the cell as described in claim 169, or the pharmaceutical composition as described in claim 170 in the preparation of a medicament for reducing apolipoprotein C3 (APOC3) in a subject. The dsRNA as described in any one of claims 1-187, the vector as described in claim 168, the cell as described in claim 169, or the pharmaceutical composition as described in claim 170, for reducing apolipoprotein C3 (APOC3) in a subject. A method for treating a subject for a disease or condition in which reduced expression of apolipoprotein C3 (APOC3) benefits, the method comprising administering to the subject an effective amount of dsRNA as claimed in any one of claims 1-187, a vector as claimed in claim 168, a cell as claimed in claim 169, or a pharmaceutical composition as claimed in claim 170. The use of the dsRNA as described in any one of claims 1-187, the vector as described in claim 168, the cell as described in claim 169, or the pharmaceutical composition as described in claim 170 in the preparation of a medicament for treating a disease or condition in which a subject benefits from reduced expression of apolipoprotein C3 (APOC3). The dsRNA as described in any one of claims 1-187, the vector as described in claim 168, the cell as described in claim 169, or the pharmaceutical composition as described in claim 170, for treating a disease or condition in a subject that benefits from reduced expression of apolipoprotein C3 (APOC3). A method for preventing at least one symptom in a subject suffering from a disease or condition that benefits from reduced expression of apolipoprotein C3 (APOC3), the method comprising administering to the subject an effective amount of dsRNA as claimed in any one of claims 1-187, a vector as claimed in claim 168, a cell as claimed in claim 169, or a pharmaceutical composition as claimed in claim 170. The use of the dsRNA as described in any one of claims 1-187, the vector as described in claim 168, the cell as described in claim 169, or the pharmaceutical composition as described in claim 170 in the preparation of a medicament for the prevention of at least one symptom in a subject suffering from a disease or condition that benefits from reduced expression of apolipoprotein C3 (APOC3). The dsRNA as described in any one of claims 1-187, the vector as described in claim 168, the cell as described in claim 169, or the pharmaceutical composition as described in claim 170, for the prevention of at least one symptom in a subject suffering from a disease or condition that benefits from reduced expression of apolipoprotein C3 (APOC3). The method, use, or application as described in any one of claims 175-180 is characterized in that, The diseases or conditions that benefit from reduced expression of apolipoprotein C3 (APOC3) are APOC3-mediated or APOC3-related diseases. The method, use, or application as described in claim 181, characterized in that, The APOC3-mediated or APOC3-related diseases are selected from the group consisting of: hyperlipidemia, hypertriglyceridemia, stroke, atherosclerosis, thrombosis, coronary heart disease, aortic stenosis, severe hypertriglyceridemia (sHTG), or familial chylomicronemia syndrome (FCS). The method of treating a subject for a disease or condition that benefits from reduced apolipoprotein C3 (APOC3) expression as described in claim 175, the method of preventing at least one symptom in a subject suffering from a disease or condition that benefits from reduced apolipoprotein C3 (APOC3) expression as described in claim 178, or the method of reducing apolipoprotein C3 (APOC3) in a subject as described in claim 172, characterized in that, This includes administering the dsRNA, vector, cell, or pharmaceutical composition to the subject subcutaneously, locally, or intravenously. The method as described in claim 183, characterized in that, The subjects were humans.
